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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 78, Revision 1 
(FGE.78Rev1): 
Consideration of aliphatic and alicyclic and aromatic hydrocarbons 
evaluated by JECFA (63rd meeting) structurally related to aliphatic and 
aromatic hydrocarbons evaluated by EFSA in FGE.25Rev21 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a 
group of 24 aliphatic, alicyclic and aromatic hydrocarbons evaluated by the JECFA (65th meeting). In the 
previous version of FGE.78, the Panel concluded that for 13 substances no applicable NOAEL was available for 
the substance itself or on a structurally related compound and therefore further data were required. Additional 
data (long term study of toxicity, mutagenicity studies and new tonnage figure) have now become available for 
beta-myrcene [FL-no: 01.008] and the present revision of FGE.78, FGE.78Rev1, includes the evaluation of 
these data. The substances were evaluated through a stepwise approach (the Procedure) that integrates 
information on structure-activity relationships, intake from current uses, toxicological threshold of concern, and 
available data on metabolism and toxicity. Two substances [FL-no: 01.011 and 01.013] are genotoxic in vitro 
and potentially carcinogenic, and are therefore not evaluated using the Procedure. The Panel concluded that the 
nine substance [FL-no: 01.002, 01.005, 01.006, 01.010, 01.016, 01.019, 01.020, 01.045 and 01.077] do not give 
rise to safety concerns at the levels of dietary intake, estimated on the basis of the MSDI approach. For 13 
substances [FL-no: 01.003, 01.004, 01.007, 01.008, 01.009, 01.014, 01.017, 01.018, 01.024, 01.026, 01.029, 
01.040 and 01.061] additional toxicity data are requested. For one substance [FL-no: 01.024] EU production 
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figure is needed to finalise the evaluation. Besides the safety assessment of these substances, the specifications 
for the materials of commerce have been considered. For two substances [FL-no: 01.018 and 01.061] the 
isomeric composition is lacking. For 14 substances [FL-no: 01.004, 01.007, 01.008, 01.009, 01.017, 01.018, 
01.019, 01.020, 01.024, 01.026, 01.029, 01.040, 01.045 and 01.061] further information on the composition of 
mixture is requested. 
© European Food Safety Authority, 2011 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000. These flavouring substances are listed in the Register, which was adopted by 
Commission Decision 1999/217/EC and its consecutive amendments. 
The present consideration concerns 24 aliphatic, alicyclic and aromatic hydrocarbons evaluated by the 
JECFA (65th meeting). The Panel concluded that the 24 substances are structurally related to the group 
of 37 aliphatic and aromatic hydrocarbons evaluated by EFSA in the Flavouring Group Evaluation 25, 
Revision 2 (FGE.25Rev2).  
The Panel agrees with the application of the Procedure as performed by the JECFA for eight of the 24 
substances considered in this FGE [FL-no: 01.002, 01.005, 01.006, 01.016, 01.019, 01.020, 01.045 
and 01.077]. 
Two substances [FL-no: 01.011 and 01.013] are genotoxic in vitro and there are unresolved problems 
with potential carcinogenicity and therefore the Panel concluded that they cannot be evaluated using 
the Procedure. 
For the following 14 substances [FL-no: 01.003, 01.004, 01.007, 01.008, 01.009, 01.010, 01.014, 
01.017, 01.018, 01.024, 01.026, 01.029, 01.040 and 01.061] it cannot be concluded that they are 
metabolised to innocuous substances and therefore their evaluation should proceed along the B-side of 
the Procedure. For one of these substances, 1-isopropenyl-4-methylbenzene [FL-no: 01.010] from 
subgroup IVe (alkyl substituted benzene hydrocarbons), a NOAEL was available, giving an adequate 
margin of safety compared to the estimated level of intake. For 13 substances no applicable NOAEL is 
available for the substance itself or on a structurally related compound and therefore further data are 
required. 
For one substance [FL-no: 01.024] the JECFA evaluation is only based on MSDI values derived from 
production figure from the USA. EU production figure is needed in order to finalise the evaluation of 
this substance.  
For two substances use levels have been provided by the Industry [FL-no: 01.008 and 01.026]. The 
mTAMDI figures calculated were above the threshold of concern for structural class I to which the 
two substances belong. For these two substances more reliable exposure data are needed. On the basis 
of such additional data these flavouring substances should be reconsidered using the Procedure. For 
the remaining 22 substances evaluated through the Procedure use levels are needed to calculate the 
mTAMDIs in order to identify those flavouring substances that need more refined exposure 
assessment to finalise the evaluation. 
In order to determine whether the conclusion for the 24 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
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specifications including complete purity criteria and identity are available for 10 of the 24 JECFA 
evaluated substances. For two substances [FL-no: 01.018 and 01.061] information on the isomeric 
composition is lacking and for 14 substances [FL-no: 01.004, 01.007, 01.008, 01.009, 01.017, 01.018, 
01.019, 01.020, 01.024, 01.026, 01.029, 01.040, 01.045 and 01.061] further information on the 
composition of the mixture is requested.  
Thus, for 14 substances [FL-no: 01.004, 01.007, 01.008, 01.009, 01.017, 01.018, 01.019, 01.020, 
01.024, 01.026, 01.029, 01.040, 01.045 and 01.061] the Panel has reservations (no European 
production volumes available, preventing them from being evaluated using the Procedure, and/or 
missing information on stereoisomerism/composition of mixture). For two of the 24 JECFA evaluated 
substances the Procedure could not be applied [FL-no: 01.011 and 01.013] due to concern with respect 
to genotoxicity and carcinogenicity. For 13 of the 24 JECFA evaluated aliphatic, alicyclic and 
aromatic hydrocarbons [FL-no: 01.003, 01.004, 01.007, 01.008, 01.009, 01.014, 01.017, 01.018, 
01.024, 01.026, 01.029, 01.040 and 01.061] additional toxicity data are requested. For the remaining 
six substances [FL-no: 01.002, 01.005, 01.006, 01.010, 01.016 and 01.077] the Panel agrees with 
JECFA conclusion “no safety concern at estimated levels of intake as flavouring substances” based on 
the MSDI approach. 
KEY WORDS 
Safety, flavouring, aliphatic, alicyclic, aromatic, hydrocarbons, JECFA, 63rd meeting, FGE.25Rev2, 
FGE.78.  
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a).  
Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the 
Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered 
by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is 
necessary. 
In the period 2000 – 2008, during its 55th, 57th, 59th, 61st, 63rd, 65th, 68th and 69th meetings, the JECFA 
evaluated about 1000 substances, which are in the EU Register. 
TERMS OF REFERENCE 
EFSA is requested to consider the JECFA evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000 (EC, 2000a). These flavouring substances are listed in the Register which was adopted 
by Commission Decision 1999/217 EC (EC, 1999a) and its consecutive amendments. 
In addition, in letter of 10 February 2010 the Commission requested EFSA to carry out a re-evaluation 
of flavouring substance myrcene [FL-no: 01.008] based on additional toxicity data: 
“The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on β-myrcene [FL-no: 01.008], α-cedrene [FL-no: 01.022], 2,6-dimethylocta-2,4,6-triene 
[FL-no: 01.035], longifolene [FL-no: 01.047] and cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064]    
in accordance with Commission Regulation (EC) No 1565/2000, by end 2010”.   
The deadline of the Terms of Reference was negotiated to end 2014. 
α-Cedrene [FL-no: 01.022], 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], longifolene [FL-no: 
01.047] and cis-3,7-dimethyl-1,3,6-octatriene [FL-no: 01.064] were re-evaluated in FGE.25Rev2. 
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. 
This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has 
been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the 
“JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
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substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be put through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006c). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended that 
the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (“Do the condition of 
use result in an intake greater than 1.5 microgram per day?”)” (JECFA, 1999b).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 microgram per person per day. 
Genotoxicity 
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As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a 
possible genotoxic potential of the flavouring substances or of structurally related substances. 
Generally, substances for which the Panel has concluded that there is an indication of genotoxic 
potential in vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are 
provided. Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated 
through the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE 
FGE Opinion 
adopted by 
EFSA 
Link No. of candidate 
substances 
78 6 March 2008 http://www.efsa.europa.eu/en/scdocs/scdoc/931.htm 24 
78Rev1 18 May 2011  24 
 
The present revision of FGE.78, Revision 1 concerns the re-consideration of one JECFA evaluated 
substance considered in FGE.78.  
In FGE.78, which contains 24 aliphatic, alicyclic and aromatic hydrocarbons, the Panel concluded that 
for 13 substances no applicable NOAEL was available for the substance itself or on a structurally 
related compound and therefore further data are required. 
Additional data (long term study of toxicity, mutagenicity studies and new tonnage figure) have now 
become available for beta-myrcene [FL-no: 01.008] and the present revision of FGE.78, FGE.78Rev1 
includes the evaluation of these data submitted by the Industry (Flavour Industry, 2010a). 
After publication of FGE.78, the JECFA has re-evaluated flavouring substances for which estimated 
intake was originally based on anticipated poundage data (JECFA, 2009c), but for which new tonnage 
data were submitted to the JECFA by Industry. These new tonnage figures are included in the present 
FGE for [FL-no: 01.029 and 01.040]. 
1. Presentation of the Substances in the JECFA Flavouring Group 
1.1. Description 
1.1.1. JECFA Status 
The JECFA has evaluated two groups of flavouring substances at their 63rd meeting: a group of 20 
substances consisting of aliphatic and alicyclic hydrocarbons and another group of five aromatic 
hydrocarbons. One of the substances, d-limonene ([FL-no: 01.045], JECFA-no: 1326), was at the 39th 
meeting allocated an acceptable daily intake (ADI) of 0-1.5 mg/kg body weight (bw). This ADI was 
withdrawn at the 41st meeting and replaced by an “ADI not specified”. One of the substances in the 
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group of aliphatic and alicyclic hydrocarbons is not in the Register (cadinene – mixture of isomers, 
JECFA-no: 1346). This consideration will therefore deal with 24 JECFA evaluated aliphatic, alicyclic 
and aromatic hydrocarbons. 
1.1.2. EFSA Considerations 
The Panel concluded that all the 24 substances in the JECFA flavouring group of aliphatic, alicyclic 
and aromatic hydrocarbons are structurally related to the group of aliphatic and aromatic hydrocarbons 
evaluated by EFSA in the Flavouring Group Evaluation 25, Revision 2 (FGE.25Rev2). 
Because of the structural diversity within this group, EFSA subdivided the substances considered in 
FGE.25Rev2 into eight subgroups. For the sake of clarity and consistency, the substances evaluated 
previously by the JECFA which are considered in the present evaluation have been allocated to the 
corresponding subgroups. Some additional subgroups have been created for substances which do not 
bear structural similarity to any of the flavouring substances considered in FGE.25, Revision 2 (e.g. 
the biphenyls). The subgrouping has been shown in Table 4.1 in Section 4.3. 
1.2. Isomers 
1.2.1. JECFA Status 
The following 10 substances [FL-no: 01.003, 01.004, 01.006, 01.007, 01.009, 01.017, 01.024, 01.026, 
01.029 and 01.045] in the group of 24 JECFA evaluated aliphatic, alicyclic and aromatic hydrocarbons 
have one or more chiral centres and the following three [FL-no: 01.018, 01.040 and 01.061] can exist 
as geometrical and/or other isomers. 
1.2.2. EFSA Considerations 
Information is lacking about the isomerism for the two substances [FL-no: 01.018, and 01.061] and 
about the composition of the mixture of 14 substances [FL-no: 01.004, 01.007, 01.008, 01.009, 
01.017, 01.018, 01.019, 01.020, 01.024, 01.026, 01.029, 01.040, 01.045 and 01.061]. 
1.3. Specifications 
1.3.1. JECFA Status 
The JECFA specifications are available for all 24 substances (JECFA, 2005b) (see Table 1). 
1.3.2. EFSA Considerations 
The available specifications are considered adequate for 10 substances. Information on isomerism 
and/or information on composition of mixture is lacking for 14 substances [FL-no: 01.004, 01.007, 
01.008, 01.009, 01.017, 01.018, 01.019, 01.020, 01.024, 01.026, 01.029, 01.040, 01.045 and 01.061] 
(see Section 1.2). 
2. Intake Estimations 
2.1. JECFA Status 
For 23 of the 24 substances evaluated through the JECFA Procedure intake data are available for the 
EU (see Table 3.1). For the remaining substance production figure is only available for the USA. 
Flavouring Group Evaluation 78, Revision 1
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2.2. EFSA Considerations 
For one substance [FL-no: 01.024] no production figure is available for Europe, so a MSDI value for 
the EU cannot be calculated for this substance. 
Only for two of the 24 JECFA evaluated substances normal and maximum use levels have been 
provided by the Flavour Industry [FL-no: 01.008 and 01.026] (EFFA, 2005a) (see Table 2.2.1). Based 
on these normal use levels, mTAMDI figure (see Table 2.2.2) can be calculated (EC, 2000a; EFSA, 
2004d). 
Table 2.2.1  Normal and Maximum use levels (mg/kg) available for JECFA evaluated substances in 
FGE.78Rev1 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
01.008 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
01.026 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
 
 
Table 2.2.2  Estimated intakes based on the MSDI and the mTAMDI approach 
FL-no EU Register name MSDI – EU 
(μg/capita/day) 
MSDI – USA 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
01.002 1-Isopropyl-4-methylbenzene 926 472  Class I 1800 
01.003 Pin-2(10)-ene 1300 759  Class I 1800 
01.005 Terpinolene 660 70  Class I 1800 
01.006 alpha-Phellandrene 79 410  Class I 1800 
01.007 beta-Caryophyllene 330 508  Class I 1800 
01.009 Camphene 13 28  Class I 1800 
01.010 1-Isopropenyl-4-methylbenzene 18 0.3  Class I 1800 
01.016 1,4(8),12-Bisabolatriene 13 10  Class I 1800 
01.017 Valencene 53 26  Class I 1800 
01.018 beta-Ocimene 55 11  Class I 1800 
01.019 alpha-Terpinene 28 93  Class I 1800 
01.020 gamma-Terpinene 1200 321  Class I 1800 
01.024 beta-Bourbonene ND 0.2  Class I 1800 
01.026 1(5),7(11)-Guaiadiene 0.012 3 3900 Class I 1800 
01.029 delta-3-Carene 290 40  Class I 1800 
01.040 alpha-Farnesene 0.61 40  Class I 1800 
01.061 Undeca-1,3,5-triene 0.24 0.2  Class I 1800 
01.077 1-Methyl-1,3-cyclohexadiene 0.012 313  Class I 1800 
01.008 Myrcene 290 153 3900 Class I 1800 
01.004 Pin-2(3)-ene 1800 2444  Class I 1800 
01.045 d-Limonene 34000 12726  Class I 1800 
01.011 4-Methyl-1,1'-biphenyl 0.0085 0.08  Class III 90 
01.013 Biphenyl 0.00085 0.7  Class III 90 
01.014 1-Methylnaphthalene 0.73 0.06  Class III 90 
3. Genotoxicity Data 
3.1. Genotoxicity Studies – Text Taken4 from the JECFA (JECFA, 2006a) 
Aliphatic and alicyclic hydrocarbons 
In vitro 
                                                     
 
4 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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No evidence of mutagenicity was observed in Ames assays when camphene ([FL-no: 01.009]; up to 
84,200 µg/plate), beta-caryophyllene ([FL-no: 01.007]; up to 150,000 µg/plate), d-limonene ([FL-no: 
01.045]; up to 150,000 µg/plate), beta-myrcene (FL-no: [FL-no: 01.008]; up to 10,000 µg/plate), α-
pinene ([FL-no: 01.004] (pin-2(3)-ene); up to 25,000 µg/plate), beta-pinene ([FL-no: 01.003] (pin-
2(10)-ene); up to 5000 µg/plate), or p-mentha-1,4-diene ([FL-no: 01.020] (gamma-terpinene); up to 
50,000 µg/plate) were incubated with Salmonella typhimurium strains TA97, TA98, TA100, TA1535, 
TA1537, TA1538, and/or UTH8413, UTH8414, or TA102 with and without metabolic activation 
(Rockwell and Raw, 1979; Florin et al., 1980; DeGraff, 1983a; Haworth et al., 1983; Jagannath, 
1984a; Jagannath, 1984b; Connor et al., 1985; Heck et al., 1989; NTP, 1990e; Müller et al., 1993; 
NTP, 2004b; NTP, 2004c). Without metabolic activation, delta-3-carene [FL-no: 01.029] at doses of 
between 2157 and 4314 µg/plate gave positive results in the Ames assay in S. typhimurium strains 
TA100 and TA102, but gave negative results in both strains with metabolic activation (Kurttio et al., 
1990). delta-3-Carene at doses of up to 4314 µg/plate also gave negative results in S. typhimurium 
strain TA98 with and without metabolic activation (Kurttio et al., 1990). In one Ames assay with S. 
typhimurium strains TA98, TA100, TA1535 and TA1537, the beta-isomer of cadinene (JECFA-no: 
1346) gave negative results at doses of up to 10 000 and 3333 µg/plate, respectively, with and without 
metabolic activation (Haworth et al., 1983; NTP, 2004e). In another Ames assay, cadinene (isomer not 
specified) gave equivocal/weak positive results at doses of up to 10 000 µg/plate in S. typhimurium 
strains TA97 and TA100 with metabolic activation, but gave negative results at doses of up to 100 
µg/plate in both strains without metabolic activation, as well as in strains TA98, TA1535 and TA1537 
with and without metabolic activation (NTP, 2004d).  
Camphene ([FL-no: 01.009]; 1.4 - 136.2 µg/ml), beta-caryophyllene ([FL-no: 01.007]; 2.0 - 204.4 
µg/ml), alpha-phellandrene ([FL-no: 01.006]; 4.5 - 136.2 µg/ml), and beta-pinene (FL-no: 01.003; 4.5 
- 136.2 µg/ml) did not induce sister chromatid exchanges (SCE) in Chinese hamster ovary cells 
without metabolic activation (Sasaki et al., 1989).  
Beta-caryophyllene ([FL-no: 01.007]; up to 10 000 µg/ml), alpha-pinene ([FL-no: 01.004]; up to 10 
000 µg/ml), and p-mentha-1,4-diene ([FL-no: 01.020]; up to 30 µg/ml) did not induce unscheduled 
DNA synthesis in rat hepatocytes (Heck et al., 1989).  
d-limonene [FL-no: 01.045] did not induce genetic effects when tested in Saccharomyces cerevisiae 
strain MP1, without metabolic activation, at concentrations of up to 230 mmol/l (Fahrig, 1984). In 
Chinese hamster ovary cells, d-limonene did not induce chromosomal aberrations at concentrations of 
10 - 500 µg/ml, or SCE at concentrations of 1.4 - 162 µg/ml, with and without metabolic activation 
(Sasaki et al., 1989; Anderson et al., 1990; NTP, 1990e). In an assay for forward mutation in mouse 
lymphoma cells, d-limonene produced negative results in L5178Y cells with and without metabolic 
activation, at a concentration of up to 100 µg/ml (Heck et al., 1989; Myhr et al., 1990; NTP, 1990e). 
When incubated with Syrian hamster embryo cells, limonene (isomer not specified) did not induce cell 
transformation in one assay at a concentration of up to 100 µg/ml (Pienta, 1980), while in another 
assay concentrations up to 408.7 µg/ml increased the transformation frequency, albeit not in a 
statistically significant manner (Rivedal et al., 2000). The latter study also tested the effects of 
limonene (isomer not specified) on gap junction intercellular communication in Syrian hamster 
embryo cells. Limonene at concentrations of 1.4 - 136.2 µg/ml did not show effects (Rivedal et al., 
2000). 
With and without metabolic activation, myrcene [FL-no: 01.008] did not induce gene mutations at the 
hypoxanthine guanine phosphoribosyl transferase (Hprt) locus in Chinese hamster V79 cells, at 
concentrations of up to 1000 µg/ml (Kauderer et al., 1991), nor did it induce SCE in these cells at 
concentrations up to 500 µg/ml (Röscheisen et al., 1991). Myrcene also did not induce SCE or 
chromosomal aberrations in human lymphocytes, with and without metabolic activation, at 
concentrations of up to 1000 µg/ml (Kauderer et al., 1991), nor did it induce SCE in hepatic tumour 
cells, at concentrations of up to 500 µg/ml, although a slight, reproducible but not dose-dependent 
increase was noted (Röscheisen et al., 1991).  
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The beta-isomer of cadinene (No. 1346, not in Register) gave negative results in an assay for forward 
mutation in mouse lymphoma cells, at concentrations of up to 46.2 µg/ml without metabolic 
activation, and at up to 73.9 µg/ml with metabolic activation (NTP, 2004f). In Chinese hamster ovary 
cells, this beta-isomer did not induce chromosomal aberration with or without metabolic activation at 
concentrations of 24.9 - 40 µg/ml, or SCE with metabolic activation at concentrations of up to 31.1 
µg/ml (NTP, 2004g). Without metabolic activation, an equivocal result was obtained for induction of 
SCE, at concentrations up to 26.6 µg/ml (NTP, 2004f). 
In a study conducted in vivo-in vitro, designed to investigate the mutagenicity of urinary metabolites 
of a number of food additives, Sprague-Dawley rats were given a single dose of 0.5 ml of camphene 
(FL-no: 01.009; approximately 1684 mg/kg bw) and alpha-pinene (FL-no: 01.004; approximately 
1718 µg/kg bw) via gavage and the urine was collected for 24 h. Three types of urine sample were 
tested in the Ames assay with S. typhimurium strains TA98 and TA100 with metabolic activation: a 
direct urine sample, a urine-ether extract, and the aqueous fraction of the urineether extract. The urine 
samples of rats treated with alpha-pinene did not show any evidence of mutagenicity, either in the 
presence or absence of beta-glucuronidase. Of the urine samples of camphene-treated rats only the 
urine-ether extract showed a weak mutagenic response, and only in TA100, not in TA98 (Rockwell 
and Raw, 1979). 
In vivo 
In a mammalian spot test, no evidence of mutagenicity was observed in mouse C57BLxT embryos in 
utero after intraperitoneal injection of the dam with d-limonene [FL-no: 01.045] at a dose of 215 
mg/kg bw per day on days 9 and 10 of gestation (Fahrig, 1984). 
In an assay for cytogenetic changes in bone marrow, groups of Wistar rats (two or four of each sex per 
group) were given myrcene [FL-no: 01.008] at a dose of 100, 500, or 1000 mg/kg bw via gavage. A 
negative control group (two rats of each sex) received only the vehicle (corn oil) via gavage, while a 
positive control group (two rats of each sex) received cyclophosphamide at a dose of 30 mg/kg bw via 
intraperitoneal injection. A mitotic inhibitor (colchicine, administered at a dose of 5 mg/kg bw via 
intraperioneal injection) was administered 1 h before sacrifice at 24 or 48 h after treatment, at which 
time the bone-marrow cells were harvested. Compared with the negative control group, treatment with 
myrcene did not result in an increase of metaphase cells with chromosomal aberrations upon 
examination at 24 or 48 h. In contrast, in the positive control group chromosomal aberrations were 
found in 19 % of the bone-marrow metaphase cells examined. Although not clastogenic, myrcene 
caused a dose-dependent increase in the mitotic index in bone-marrow cells, indicating that it was 
present at a sufficient dose in the target tissue (Zamith et al., 1993).  
An assay for micronucleus formation in mouse peripheral blood erythrocytes was performed, with 
samples of peripheral blood obtained within 24 h of the final exposure in a 13-week study of toxicity 
in which male and female B6C3F1 mice were given myrcene [FL-no: 01.008] at a dose of up to 2000 
mg/kg bw per day via gavage. Scoring of 1000 normochromatic erythrocytes (NCEs) for micronuclei 
revealed no increase in micronucleated NCEs at any dose (NTP, 2004h). 
Conclusion on genotoxicity on aliphatic/alicyclic hydrocarbons 
Seven substances in this group of flavouring agents have been tested in the Ames assay and found not 
to be mutagenic in bacteria in vitro. One flavouring agent, delta-3-carene, produced a positive result in 
this assay, only without metabolic activation, in S. typhimurium strains TA100 and TA102 but not 
TA98. Another flavouring agent, cadinene (isomer not specified), gave weakly positive results in the 
Ames assay, only with metabolic activation, in S. typhimurium strains TA97 and TA100 but not TA98, 
TA1535, and TA1537.  
In mammalian cell systems, predominantly negative results were obtained for representative members 
of this group with respect to induction of SCE, chromosomal aberrations, unscheduled DNA synthesis, 
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and gene mutations. In assays for cell transformation in Syrian hamster embryo cells, limonene 
(isomer not specified) gave negative results in one assay, but weak positive results in another, the 
increase in transformation frequency being not statistically significant.  
Myrcene and d-limonene showed no signs of genetic toxicity in cytogenetic assays for micronucleus 
formation in bone marrow and peripheral erythrocytes (myrcene) and a mammalian spot test (d-
limonene) performed in vivo.  
On the basis of the results of available studies of genotoxicity, the Committee concluded that the 
flavouring agents in this group of aliphatic and alicyclic hydrocarbons are not genotoxic. 
Aromatic hydrocarbons 
In vitro 
No evidence of mutagenicity was observed in standard or modified Ames assays when p-cymene 
([FL-no: 01.002]; up to 85,300 µg/plate), biphenyl ([FL-no: 01.013]; up to 10,000 µg/plate), 4-
methylbiphenyl ([FL-no: 01.011]; up to 1000 µg/plate), or 1-methylnaphthalene ([FL-no: 01.014]; up 
to 4266 µg/plate) were incubated with Salmonella typhimurium strains TA97, TA98, TA100, TA1535, 
TA1537, TA1538, and/or TA1532, TA2636, TA2637, G46, C3076, or D3052 with and without 
metabolic activation (Clark et al., 1977; Clark et al., 1979; Anderson and Styles, 1978; Rockwell and 
Raw, 1979; Florin et al., 1980; Hirayama et al., 1981; Probst et al., 1981; Haworth et al., 1983) and 
(Pagano et al., 1983; Nohmi et al., 1985; Brams et al., 1987; Houk et al., 1989; NTP, 2004i; NTP, 
2004j; NTP, 2004k; Zeiger et al., 1992)). Biphenyl also gave negative results when incubated with 
Escherichia coli strains WP2 and WP2 uvrA- in the modified Ames test (Probst et al., 1981), strain 
PQ37 in the SOS chromotest (up to 154 µg/ml) (Brams et al., 1987), and with strains WP2, WP2 uvrA, 
WP100, and CM571 in a test for DNA repair (up to 4000 µg/disk) (Hirayama et al., 1981).  
In contrast to the negative results obtained for biphenyl in S. typhimurium and E. coli systems, 
biphenyl [FL-no: 01.013] produced genetic effects in an assay with Saccharomyces cerevisiae strain 
D7, with and without metabolic activation, at concentrations of up to 1 mmol/l (Pagano et al., 1983). 
In an assay for forward mutation in mouse lymphoma cells, biphenyl produced significant increases in 
mutation frequency in L5178Y cells at concentrations of 45.6 - 60.9 µg/ml without metabolic 
activation, and 3.1 - 9.3 µg/ml with activation (Wangenheim and Bolcsfoldi, 1988). However, the 
increases were ≥ 2-fold only at 60.9 µg/ml without activation, and 6.2 - 9.3 µg/ml with activation. At 
these concentrations, cell viability was ≤ 15 %. At lower concentrations of 15.2 - 30.4 µg/ml without 
metabolic activation, and 0.8 - 1.5 µg/ml with activation, biphenyl gave negative results (Wangenheim 
and Bolcsfoldi, 1988). Cell viability was much higher at these lower concentrations (at least 49 %). 
Biphenyl did not induce sister chromatid exchanges (SCE) or chromosomal aberrations in Chinese 
hamster Don cells at concentrations of up to 154 µg/ ml without metabolic activation (Abe & Sasaki, 
1977), nor did it induce unscheduled DNA synthesis in rat hepatocytes at concentrations of 0.002 - 
154 µg/ml (Brouns et al., 1979; Probst et al., 1981; Hsia et al., 1983).  
In a study designed to investigate the mutagenicity in vivo-in vitro of urinary metabolites of a number 
of food additives, Sprague-Dawley rats were given 0.5 ml of p-cymene ([FL-no: 01.002]; 
approximately 1706 mg/kg bw) by gavage and urine was collected for 24 h. Three types of urine 
samples were tested in the Ames assay with S. typhimurium strains TA98 and TA100 with metabolic 
activation: a direct urine sample, a urine-ether extract, and the aqueous fraction of the urine–ether 
extract. The urine samples of rats treated with p-cymene did not show any evidence of mutagenicity, 
either in the presence or absence of beta-glucuronidase (Rockwell and Raw, 1979). 
 
Conclusion on genotoxicity on aromatic hydrocarbons 
 
Four substances in this group of flavouring agents have been tested in the Ames assay and found not 
to be mutagenic in vitro in bacteria. In addition to showing no mutagenic potential in the Ames assay, 
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biphenyl produced negative results in E. coli in the SOS chromotest and DNA repair test. On the other 
hand, biphenyl produced genetic effects in yeast (S. cerevisiae). In mammalian cell systems, negative 
results were obtained for biphenyl with respect to induction of SCE, chromosomal aberration, and 
unscheduled DNA synthesis. The positive finding for biphenyl in an assay for forward mutation in 
mouse lymphoma cells was obtained at near lethal concentrations. On the basis of the results of 
available studies of genotoxicity, the Committee concluded that the flavouring agents in this group of 
aromatic hydrocarbons are not genotoxic. 
For a summary of in vitro / in vivo genotoxicity data considered by JECFA, see Table 2.1 and 2.2. 
3.2. Genotoxicity Studies - Text Taken5 from EFSA FGE.25Rev2 (EFSA, 2011k) 
In vitro / in vivo 
Data from in vitro tests are available for six candidate substances, subgroup I: [FL-no: 01.038] and 
[FL-no: 01.057]; subgroup II: [FL-no: 01.037]; subgroup IVb: [FL-no: 01.051 and 01.053]; subgroup 
V6: [FL-no: 01.047] and 11 supporting substances, one from subgroup II, four from subgroup III, one 
from subgroup IVb, five from subgroup V (for one of these [FL-no: 01.004] also data for separate 
stereoisomers were available (+ and -)-alpha-pinene (pin-2(3)-ene)(isomer of [FL-no: 01.004]), and 
one structurally related substance (2-methylbuta-1,3-diene (isoprene)) from subgroup II. Data for two 
of the candidate substances [FL-no: 01.051 and 01.053] (subgroup IVb), data for four supporting 
substances [FL-no: 01.008] (subgroup II), [FL-no: 01.019] (subgroup III), [FL-no: 01.014] (subgroup 
IVb) [FL-no: 01.004] (subgroup V) and data for the structurally related substance from subgroup II are 
considered valid.  
Data from in vivo tests are available for one candidate substance, subgroup IVb: [FL-no: 01.053], for 
two supporting substances (one from subgroup II and one from subgroup III) and for one substance 
structurally related to subgroup II (2-methylbuta-1,3-diene). 
There are no data available on candidate or supporting substances from subgroups IVa, IVc and VI. 
Candidate substances 
Subgroup I 
The two candidate substances [FL-no: 01.038 and 01.057] tested in vitro for bacterial gene mutations 
gave negative results in bacterial reverse gene mutation tests and for mammalian cell gene mutations.  
Subgroup II 
For the six candidate substances in subgroup II [FL-no: 01.032, 01.035, 01.037, 01.064, 01.070 and 
01.078] there are, except for one negative bacterial reverse gene mutation test (“Ames test”), no 
genotoxicity data available.  
The available in vivo studies on the structurally related substance 2-methylbuta-1,3-diene (isoprene) 
reported a negative result in a valid chromosomal aberration assay in the bone marrow of mice after 12 
days of inhalatory exposure to isoprene. However, isoprene induced sister chromatid exchanges (SCE) 
in the bone marrow and micronuclei in peripheral blood cells of mice after 12 days of inhalatory 
exposure in two valid studies carried out within NTP. Induction of micronuclei in peripheral blood 
cells of mice has also been reported after inhalatory exposure for 13 weeks. In contrast, inhalatory 
exposure of isoprene to male and female rats for four weeks did not result in an increase in the 
                                                     
 
5 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
6 An Ames test with cedrene washed (unspecified cedrene) was also submitted, but an adequate identification of the substance studied was not possible. 
Therefore the study is not further discussed. 
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frequency of micronuclei in the lung fibroblasts. The validity of the latter two studies cannot be 
evaluated due to limited details available. Isoprene has been reported to bind covalently to 
haemoglobin in vivo (IARC, 1999a). 
The genotoxic and carcinogenic potential of isoprene has been evaluated by IARC (1999a). It was 
concluded that there is sufficient evidence of carcinogenicity in experimental mammalians and that 
isoprene is ‘possibly carcinogenic to humans’ (Group 2B) (IARC, 1999a). Isoprene has been classified 
in the EU as a ‘Muta. Cat. 3; R68’ and ‘Carc. Cat. 2; R45’ (ECB, 2005). 
The available data on in vivo genotoxicity of 2-methylbuta-1,3-diene (synonym: isoprene) indicate a 
genotoxic potential of the substance. In the light of the evidence of carcinogenic activity of isoprene in 
rats and mice (NTP, 1999d) and the genotoxic effects of isoprene in mice and the fact that the 
structurally related substance 1,3-butadiene is classified as a genotoxic carcinogen, the Panel 
concluded that there is reason for concern with respect to genotoxicity and carcinogenicity of isoprene. 
This substance has been deleted from the Register. 
For the supporting substances beta-myrcene, several in vitro genotoxicity tests and three in vivo 
genotoxicity studies were available. All the in vitro genotoxicity tests on beta-myrcene were negative. 
Two micronucleus tests on peripheral blood cells and one chromosomal aberration assay with beta-
myrcene gave negative results. 
Conclusion on Genotoxicity for subgroup II 
The structurally related substance myrcene [FL-no: 01.008] has like former Register substance 2-
methyl-1,3-butadiene (isoprene), two conjugated terminal double bonds, but has, similar to candidate 
substance [Fl no: 01.064], a longer chain length, with 10 carbon atoms. In contrast to isoprene, the 
candidate substances in subgroup II do not contain conjugated terminal double bonds, except [FL-no: 
01.064], which, however, are very structurally related to myrcene [FL-no: 01.008]. Therefore, the 
Panel considers myrcene a better supporting substance for the substances in group II than isoprene. 
The genotoxicity data available on myrcene do not give rise to concern with respect to genotoxicity. 
Therefore, the Panel has not concern for genotoxicity for the 6 substances in subgroup II. 
Subgroup III 
For the six candidate substances in subgroup III no genotoxicity studies were available. For the four 
supporting substances, d-limonene [FL-no: 01.045], gamma-terpinene [FL-no: 01.020], alpha-
terpinene [FL-no: 01.019] and alpha-phellandrene [FL-no: 01.006], several in vitro studies on 
genotoxicity were available and they were all negative. Also two in vivo Comet assay with d-limonene 
and a study with d-limonene in BigBlueTM rats were found negative. Therefore, the Panel has no 
concern for genotoxicity for the substances in subgroup III. 
Subgroup IVb 
Naphthalene 
Naphthalene [FL-no: 01.053], which was negative in all bacterial gene mutation tests (Ames tests, Rec 
assay, Inductest) and in a unscheduled DNA synthesis (UDS) test in primary rat hepatocytes, gave a 
weakly positive result in a valid sister chromatid exchange (SCE) test both in the presence and absence 
of metabolic activation and a positive result in a valid chromosomal aberration test in the presence of 
S9. A positive result was also reported in a mammalian cell gene mutation test (mouse lymphoma 
assay). However, the validity of this study cannot be evaluated.  
The available in vivo studies on the candidate substance naphthalene [FL-no: 01.053] reported 
negative results in a valid UDS test and in two micronucleus tests, for one of which the validity cannot 
be evaluated due to insufficiently reported experimental details.  
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The genotoxicity of naphthalene [FL-no: 01.053] has been evaluated by international expert bodies 
(WHO, 1998; EU-RAR, 2003; US ATSDR, 2005). Results of the in vitro genotoxicity studies that 
were evaluated are in line with the data summarised in the present evaluation. Negative results were 
reported for all the evaluated bacterial gene mutation tests (Ames tests, Rec assays, Inductests/SOS 
response tests). For in vitro mammalian gene mutation, cytogenetic, or DNA damage assays, equally 
mixed results were reported as in the present evaluation. In addition to the studies cited in the present 
evaluation, negative results were reported for mutations at the hprt and tk locus in a human B-
lymphoblastoid cell line (Sasaki et al., 1997) and for single-strand breaks in an alkaline elution test 
with rat hepatocytes (Sina et al., 1983) as well as for some other less relevant endpoints (different cell 
transformation assays). Positive results were reported for naphthalene in a non-standard chromosomal 
aberration assay (Gollahon, 1991) and for the naphthalene metabolites 1,2- and 1,4-naphthoquinone in 
a SCE test (Wilson et al., 1996). For in vivo genotoxicity, besides the negative results from studies 
examining commonly accepted endpoints (micronuclei formation in mouse bone marrow, DNA single 
strand breaks and UDS in rat hepatocytes) as reported in the present evaluation, some positive results 
were reported for somatic mutations in D. melanogaster (Delgado-Rodriques et al., 1995), micronuclei 
in salamander larvae erythrocytes (Djomo et al., 1995), and DNA fragmentation in liver and brain 
tissue from mice and rats orally exposed to naphthalene (Bagchi et al., 2000). However, DNA 
fragmentation per se cannot be considered a specific endpoint of genotoxicity, being rather an 
indicator of cytotoxicity, in this case due to oxidative stress. Therefore, the study by Bagchi et al. 
(2000) has no relevance for the evaluation of the genotoxic potential of naphthalene. WHO (1998) 
noted that naphthalene was inactive in all short-term mutagenicity tests evaluated by IARC in 1983 
(WHO, 1998). US ATSDR (2005) concluded that the available data suggest that genotoxic action by 
the naphthalene metabolite, 1,2-naphthoquinone, is plausible and that the mutagenic/genotoxic 
potential of naphthalene and its metabolites may be weak (US ATSDR, 2005). In the EU-RAR (2003) 
it was concluded that overall, the balance of evidence indicates that naphthalene is not genotoxic (EU-
RAR, 2003). 
2-Methylnaphthalene 
The weak increases of chromosome aberrations (chromatid breaks only at the highest concentration) 
and of the SCE in cultured human lymphocytes in the presence of S9 are of doubtful relevance (Kulka 
et al., 1988). According to the authors, these effects do not indicate that 2-methylnaphthalene is a 
potentially genotoxic substance. 
The genotoxicity of 2-methylnaphthalene has been evaluated by international expert bodies (EFSA, 
2004e; US ATSDR, 2005). Results of the in vitro genotoxicity studies that were evaluated are in line 
with the data summarised in the present evaluation. Negative results were reported for all the 
evaluated bacterial gene mutation tests (Ames tests, Rec assays, Inductests/SOS response tests). 
The supporting substance, 1-methylnaphthalene, gave a weak increase, of doubtful biological 
relevance, of SCE in cultured human lymphocytes in the presence of S9 (Kulka et al., 1988). This 
effect was interpreted by the authors not to be an indication of genotoxic potential. Furthermore, 1-
methylnaphthalene gave negative results in two bacterial reverse gene mutation tests (Florin et al., 
1980; Kaden et al., 1979); and in a chromosomal aberration assay in human lymphocytes (Kulka et al., 
1988). 
Conclusion on genotoxicity for subgroup IVb 
For naphthalene there is indication of in vitro genotoxicity especially at chromosome level. However, 
this genotoxic activity is not expressed in valid in vivo assays covering different end-points (e.g. 
micronucleus, UDS and DNA single strand breaks). 
The available data on 2-methylnaphthalene, limited to the in vitro data referred to in the present 
evaluation, were considered not to give evidence for a genotoxic activity.  
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The Panel concluded that the available genotoxicity data on naphthalene and 2-methylnaphthalene do 
not preclude an evaluation of these substances through the Procedure. 
Subgroup V 
One candidate substances longifolene [FL-no: 01.047] was tested in vitro for bacterial reverse gene 
mutations and gave negative results. 
For all genotoxicity studies on supporting substances, only negative results were reported in the 
available studies except for delta-3-carene (see Table 2.3). Delta-3-carene was studied individually as 
a component in wood fumes and wood fume condensates (Kurttio et al., 1990). It was reported to be 
positive in TA100 and TA102 strains in an insufficiently reported bacterial reverse gene mutation test 
in the absence of metabolic activation at high concentrations only, while it was negative in the 
presence of metabolic activation. 
Altogether, the Panel has no concern for genotoxicity for the substances in subgroup V. 
Overall conclusion on genotoxicity:  
Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity 
could not be assessed adequately for these substances. For one structurally related substance, 2-
methylbuta-1,3-diene (synonym: isoprene) there is evidence of an in vivo genotoxic potential. 
However, the Panel concluded that the available data do not preclude evaluating the 37 candidate 
substances using the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA see Table 2.3 and 2.4. 
3.3. EFSA Considerations 
The Panel agrees with the JECFA conclusions on genotoxicity, except that the Panel has concern with 
respect to in vitro genotoxicity (absence of valid in vivo genotoxicity studies) of biphenyl [FL-no: 
01.013] and to 4-methyl-1,1-biphenyl [FL-no: 01.011] due to its structural relationship with biphenyl. 
4. Application of the Procedure 
4.1. Application of the Procedure to 24 Aliphatic, Alicyclic and Aromatic Hydrocarbons 
by the JECFA (JECFA, 2006a) 
1.2.1. Aliphatic and alicyclic hydrocarbons 
According to the JECFA all these 19 substances belong to structural class I using the decision tree 
approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded 16 aliphatic and alicyclic hydrocarbons at step A3 in the JECFA Procedure – 
i.e. the substances are expected to be metabolised to innocuous products (step 2) and the intakes for all 
substances are below the thresholds for their structural class I (step A3). For three substances, d-
limonene, myrcene and alpha-pinene [FL-no: 01.045, 01.008 and 01.004] the estimated daily intake 
exceeds the threshold for structural class I and these substances were evaluated at step A5. 
For myrcene [FL-no: 01.008] a Lowest-Observed-Effect Level (LOEL) of 250 mg/kg bw per day was 
reported for male mice and male and female rats treated by gavage for 13 weeks (NTP, 2004a), while 
the same dose was the no-observed-effect level (NOEL) in female mice. This dose is approximately 
1800 times greater than the estimated intake of myrcene from its use as a flavouring agent in Europe 
(140 µg/kg bw per day) and 83,000 times greater than the estimated intake of myrcene in the USA (3 
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µg/kg bw per day). The Committee concluded that myrcene would not pose a safety concern at 
estimated current intake. 
At its 41st meeting, the Committee established an ADI ‘not specified’ for d-limonene [FL-no: 01.045] 
on the basis of short- and long-term studies of toxicity in female rats and male and female mice, and 
studies of developmental toxicity in mice, rats and rabbits. In these studies, d-limonene was tested at 
doses ranging from 250 to 2800 mg/kg bw per day. Based on the ADI ‘not specified’, the Committee 
concluded that d-limonene would not pose a safety concern at the estimated current intakes (660 µg/kg 
bw per day in Europe and 210 µg/kg bw per day in the USA).  
No toxicological data on alpha-pinene [FL-no: 01.004] were available. d-Limonene shares structural 
characteristics with alpha-pinene in that both contain a methyl-substituted cyclohexene ring, which 
contains a second alkyl substituent. In d-limonene, this is an isopropenyl group, while in alpha-pinene 
the second substituent is a dimethyl-substituted methylene bridge. Based on these chemical structures, 
it would be predicted that the toxicity of alpha-pinene would be unlikely to exceed that of d-limonene. 
Both compounds are predicted to be metabolised to innocuous products. Metabolism of both 
compounds is by hydroxylation of the cyclohexene ring and oxidation of its methyl substituent. d-
Limonene undergoes epoxidation of the endocyclic and allylic double bonds, leading to dihydroxy 
products. Alpha-Pinene is converted to several metabolites, including d-limonene, by rat liver 
microsomes in vitro. The Committee concluded that d-limonene shared sufficient chemical and 
metabolic similarities with alpha-pinene to be used as a structural analogue for alpha-pinene at this 
step of the Procedure. The estimated current per capita intakes of alpha-pinene in Europe (36 µg/kg 
bw per day) and in the USA (41 µg/kg bw per day) are approximately 5 % and 20 %, respectively, of 
those of d-limonene, and are almost four orders of magnitude lower than the lowest doses of d-
limonene considered in the establishment of its ADI ‘not specified’. On the basis of these 
considerations, the Committee concluded that alpha-pinene would not pose a safety concern at 
estimated current intakes. 
In conclusion the JECFA evaluated the 19 substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
1.2.2. Aromatic hydrocarbons 
According to the JECFA two of these substances [FL-no: 01.002 and 01.010] belong to structural class 
I and the remaining three [FL-no: 01.011, 01.013 and 01.014] to structural class III using the decision 
tree approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded all five aromatic hydrocarbons at step A3 in the JECFA Procedure – i.e. the 
substances are expected to be metabolised to innocuous products (step 2) and the intakes for all 
substances are below the thresholds for their structural classes I and III (step A3). 
In conclusion, the JECFA evaluated all five substances as to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
The evaluations of all 24 aliphatic, alicyclic and aromatic hydrocarbons are summarised in Table 3.1. 
4.2. Application of the Procedure to Aliphatic and Aromatic Hydrocarbons in 
FGE.25Rev2 
For the safety evaluation of the 37 candidate substances from chemical group 31, the Procedure as 
outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations of these 37 
substances are summarised in Table 2. 
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Step 1 
Thirty-one of the 37 candidate substances evaluated using the Procedure are classified into structural 
class I [FL-no: 01.001, 01.022, 01.023, 01.027, 01.028, 01.030, 01.032, 01.033, 01.034, 01.035, 
01.037, 01.038, 01.039, 01.042, 01.043, 01.044, 01.046, 01.047, 01.050, 01.052, 01.054, 01.055, 
01.056, 01.057, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 01.078], two into structural class 
II [FL-no: 01.031 and 01.058], and four into structural class III, [FL-no: 01.021, 01.036, 01.051 and 
01.053], according to the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
Step 2  
On the basis of the metabolism information available, five of the six candidate substances of subgroup 
I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] and five of the six candidate substances of 
subgroup III [FL-no: 01.001, 01.027, 01.028, 01.039 and 01.046] (see Table 4.1) may be predicted to 
be metabolised to innocuous products at the estimated levels of intake based on the MSDI approach, 
and accordingly the evaluation of these 10 substances proceeds along the A-side of the Procedure 
scheme.  
The remaining candidate substance from subgroup I [FL-no: 01.050] may be biotransformed to a 
neurotoxic gamma-diketone. Three candidate substances from subgroup II [FL-no: 01.037, 01.064 and 
01.070] contain terminal double bonds in the absence of other functional groups that may provide 
alternative routes of detoxication. For the two candidate substances from subgroup IVb [FL-no: 
01.051 and 01.053] it has been shown that they may be converted to toxic metabolites. Therefore, for 
these six substances it cannot be concluded that they will be metabolised to innocuous products, and 
accordingly they proceed along the B-side of the Procedure scheme.  
For the remaining 21 candidate substances [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 
01.035, 01.036, 01.042, 01.043, 01.044, 01.047, 01.052, 01.055, 01.056, 01.058, 01.059, 01.060, 
01.066, 01.067 and 01.078] there are not sufficient data available on biotransformation to conclude 
that they will be metabolised to innocuous products, and therefore their evaluation will proceed along 
the B-side of the Procedure scheme. 
Step A3 
The five candidate substances from subgroup I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] 
and the three candidate substances from subgroup III [FL-no: 01.027, 01.028 and 01.039], proceeding 
via the A-side, have been assigned to structural class I and have estimated European daily per capita 
intakes ranging from 0.012 to 2.7 microgram (Table 3.2). These intakes are below the threshold of 
concern of 1800 microgram/person/day for structural class I. Accordingly, it is concluded that these 
eight candidate substances do not pose a safety concern as flavouring substances when used at 
estimated levels of intake, based on the MSDI approach. The two candidate substances from subgroup 
III [Fl-no: 01.001and 01.046] have an estimated European daily per capita intake of 4000 and 2100, 
respectively, which are above the threshold of concern of 1800 microgram/person/day for structural 
class I. The evaluation of these candidate substances will therefore proceed to A4 of the Procedure. 
Step A4 
The candidate substances [Fl-no: 01.001 and 01.046] or its metabolites are not endogenous. 
Step A5 
The two candidate substances [FL-no: 01.001 and 01.046] are supported by the substance [FL-no: 
01.045] for which an adequate carcinogenicity study is available. From this study a no observed 
adverse effect level (NOAEL) of 215 mg/kg bw/day can be derived. The estimated daily per capita 
intake is 4000 microgram for [FL-no: 01.001] and 2100 microgram for [FL-no: 01.046], 
corresponding to 0.07 mg/kg bw/day and 0.035 mg/kg bw/day at a body weight of 60 kg, respectively. 
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Thus, a margin of safety of 3070 can be calculated for [FL-no: 01.001] and a margin of safety of 6140 
can be calculated for [FL-no: 01.046]. These two substances are accordingly not expected to be of 
safety concern at the estimated levels of intake. 
Step B3 
The 21 candidate substances [FL-no: 01.022, 01.023, 01.030, 01.032, 01.035, 01.037, 01.042, 01.043, 
01.044, 01.047, 01.050, 01.052, 01.055, 01.056, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 
01.078] proceeding via the B-side and which have been assigned to structural class I have estimated 
European daily per capita intakes between 0.0085 and 28 microgram (Table 3.2). These intakes are 
below the threshold of concern of 1800 microgram/person/day for structural class I. Two of the 
candidate substances [FL-no: 01.031 and 01.058] proceeding via the B-side and assigned to structural 
class II, have estimated European daily per capita intakes of 0.0012 and 0.12 micrograms, 
respectively. These intakes are below the threshold of concern of 540 microgram/person/day for 
structural class II. Four candidate substances [FL-no: 01.021, 01.036, 01.051 and 01.053] proceeding 
via the B-side and assigned to structural class III, have European daily per capita intakes of 0.15, 1.2, 
0.0012 and 0.013 microgram. These intakes are below the threshold of concern for structural class III 
of 90 microgram/person/day. Accordingly, these 27 substances all proceed to step B4 of the 
Procedure. 
Step B4 
No adequate No Observed Adverse Effect Levels (NOAELs) have been submitted for any of these 27 
candidate substances  at step B4 [FL-no: 01.021, 01.022, 01.023, 01.030, 01.031, 01.032, 01.035, 
01.036, 01.037, 01.042, 01.043, 01.044, 01.047, 01.050, 01.051, 01.052, 01.053, 01.055, 01.056, 
01.058, 01.059, 01.060, 01.064, 01.066, 01.067, 01.070 and 01.078] or for any structurally related 
substances. Therefore, the Panel concluded that additional data are required for these substances. 
4.3. EFSA Considerations 
New toxicity data on beta- myrcene was submitted by the Industry. These data have been evaluated in 
detail in FGE.25Rev2. In the evaluation of the new toxicity study of beta-myrcene it was concluded in 
FGE.25Rev2 that: “No overall NOAEL from the NTP study on beta-myrcene could be allocated due 
to the observation of renal toxicity in male and female rats at all dose groups. The Panel has 
considered deriving a BMDL from the NTP study of myrcene. However, a BMDL from this study 
could not be derived since nearly 100 % incidence of nephrosis was observed in male rats already at 
the lowest dose of beta-myrcene. 
The 24 JECFA evaluated hydrocarbons and the 37 EFSA evaluated hydrocarbons are distributed into 
10 subgroups of structurally related substances by EFSA. The Panel conclusions on predictions of 
metabolism are shown in Table 4.1 below. 
 
 
 
Table 4.1 Subgroups as classified by EFSA within the groups of the JECFA evaluated hydrocarbons (JECFA, 
2006a) and the EFSA evaluated hydrocarbons in FGE.25Rev2. The JECFA evaluated hydrocarbons are listed in 
brackets. 
FL-no EU Register name Structural formula Struc. 
class 
Predicted metabolism to 
innocuous products? 
(by EFSA) 
A- or B- 
side of the 
Procedure 
(EFSA) 
A- or B- 
side of the 
Procedure 
(JECFA) 
I:  ACYCLIC ALKANES 
01.033 2,2-Dimethylhexane    I Yes A  
01.034 2,4-Dimethylhexane   I Yes A  
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Table 4.1 Subgroups as classified by EFSA within the groups of the JECFA evaluated hydrocarbons (JECFA, 
2006a) and the EFSA evaluated hydrocarbons in FGE.25Rev2. The JECFA evaluated hydrocarbons are listed in 
brackets. 
FL-no EU Register name Structural formula Struc. 
class 
Predicted metabolism to 
innocuous products? 
(by EFSA) 
A- or B- 
side of the 
Procedure 
(EFSA) 
A- or B- 
side of the 
Procedure 
(JECFA) 
01.038 Dodecane    I Yes A  
01.050 3-Methylhexane    I No (potential formation of neurotoxic 
gamma-diketone) 
B  
01.054 Pentadecane   I Yes A  
01.057 Tetradecane    I Yes A  
II:  ACYCLIC ALKENES 
01.032 2,3-Dihydrofarnesene   I No (lack of supporting data) B  
01.035 2,6-Dimethylocta-2,4,6-triene I No (lack of supporting data) B  
01.037 Dodec-1-ene I No (presence of terminal double bond 
which may give rise to reactive 
metabolites without counteracting 
metabolic options) 
B  
01.064 cis-3,7-Dimethyl-1,3,6-
octatriene 
 
I No (presence of terminal double bond 
which may give rise to reactive 
metabolites without counteracting 
metabolic options) 
B  
01.070 1-Octene  I No (presence of terminal double bond 
which may give rise to reactive 
metabolites without counteracting 
metabolic options) 
B  
01.078 2,4-Nonadiene I No (lack of supporting data) B  
(01.008) (Myrcene) 
 
I 
 
No (lack of supporting data) B A 
(01.018) (beta-Ocimene) 
 
I No (lack of supporting data) B A 
(01.040) (alpha-Farnesene) I No (lack of supporting data) B A 
(01.061) (Undeca-1,3,5-triene) I No (lack of supporting data) B A 
III:  CYCLOHEXENE HYDROCARBONS 
01.001 Limonene 
 
I Yes A  
01.046 l-Limonene 
 
I Yes A  
01.055 beta-Phellandrene 
 
I No (lack of supporting data) B  
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Table 4.1 Subgroups as classified by EFSA within the groups of the JECFA evaluated hydrocarbons (JECFA, 
2006a) and the EFSA evaluated hydrocarbons in FGE.25Rev2. The JECFA evaluated hydrocarbons are listed in 
brackets. 
FL-no EU Register name Structural formula Struc. 
class 
Predicted metabolism to 
innocuous products? 
(by EFSA) 
A- or B- 
side of the 
Procedure 
(EFSA) 
A- or B- 
side of the 
Procedure 
(JECFA) 
01.027 Bisabola-1,8,12-triene   
 
 
I Yes A  
01.028 beta-Bisabolene I Yes A  
01.039 delta-Elemene I Yes  A  
(01.005) (Terpinolene) 
 
I  A A 
(01.006) (alpha-Phellandrene) 
 
I  A A 
(01.016) (1,4(8),12-Bisabolatriene) I  A A 
(01.019) (alpha-Terpinene) 
 
I  A A 
(01.020) (gamma-Terpinene) 
 
I  A A 
(01.045) (d-Limonene) 
 
I  A A 
(01.077) (1-Methyl-1,3-cyclohexadiene) 
 
I  A A 
IV: AROMATIC HYDROCARBONS 
IVa:  CYCLOALKYL SUBSTITUTED BENZENE HYDROCARBONS 
01.031 1,2-Dihydro-1,1,6-
trimethylnaphthalene 
II No (lack of supporting data) B  
01.058 1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene    
II No (lack of supporting dat) B  
IVb:  NAPHTHALENE HYDROCARBONS 
01.051 2-Methylnaphthalene    
 
III No (known metabolism to toxic 
metabolites) 
 
B  
01.053 Naphthalene    
 
III No (known metabolism to toxic 
metabolites) 
  
B  
Flavouring Group Evaluation 78, Revision 1
 
 
22 EFSA Journal 2011; 9(6):2178 
Table 4.1 Subgroups as classified by EFSA within the groups of the JECFA evaluated hydrocarbons (JECFA, 
2006a) and the EFSA evaluated hydrocarbons in FGE.25Rev2. The JECFA evaluated hydrocarbons are listed in 
brackets. 
FL-no EU Register name Structural formula Struc. 
class 
Predicted metabolism to 
innocuous products? 
(by EFSA) 
A- or B- 
side of the 
Procedure 
(EFSA) 
A- or B- 
side of the 
Procedure 
(JECFA) 
(01.014) (1-Methylnaphthalene) 
 
III No (structurally related to FL-no: 
01.051 and 01.053) 
B A 
IVc: DIPHENYLMETHANE 
01.036 Diphenylmethane   III No (lack of supporting data) B  
IVd:  BIPHENYLS 
(01.011) (4-methyl-1,1-biphenyl)  
 
III No (anticipated to be metabolised to 
reactive metabolites responsible for 
toxicity) 
Not 
evaluated  
through the 
Procedure. 
Genotoxic in 
vitro and 
unresolved 
problems 
with 
potential 
carcinogenic
ity 
A 
(01.013) (Biphenyl) 
 
III No (anticipated to be metabolised to 
reactive metabolites responsible for 
toxicity) 
Not 
evaluated  
through the 
Procedure. 
Genotoxic in 
vitro and 
unresolved 
problems 
with 
potential 
carcinogenic
ity 
A 
IVe: ALKYL SUBSTITUTED BENZENE HYDROCARBONS 
(01.002) (1-isopropyl-4-methylbenzene) 
 
I  A A 
(01.010) (1-isopropenyl-4-
methylbenzene)  
 
I No B A 
V: BI- and TRICYCLIC, NONAROMATIC HYDROCARBONS 
01.021 Delta-Cadinene III No (lack of supporting data) B  
01.022 alpha-Cedrene HH I No (lack of supporting data) B  
01.023 1(5),11-Guaiadiene I No (lack of supporting data) B  
01.030 beta-Cubebene I No (lack of supporting data) B  
01.044 Isolongifolene I No (lack of supporting data) B  
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Table 4.1 Subgroups as classified by EFSA within the groups of the JECFA evaluated hydrocarbons (JECFA, 
2006a) and the EFSA evaluated hydrocarbons in FGE.25Rev2. The JECFA evaluated hydrocarbons are listed in 
brackets. 
FL-no EU Register name Structural formula Struc. 
class 
Predicted metabolism to 
innocuous products? 
(by EFSA) 
A- or B- 
side of the 
Procedure 
(EFSA) 
A- or B- 
side of the 
Procedure 
(JECFA) 
01.047 Longifolene 
H
H
H
I No (lack of supporting data) B  
01.052 alpha-Muurolene I No (lack of supporting data) B  
01.056 alpha-Santalene   I No (lack of supporting data) B  
01.059 4(10)-Thujene 
 
 No (lack of supporting data) B  
01.060 1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)
]heptane   
 
I No (lack of supporting data) B  
01.066 2-Cedrene I No (lack of supporting data) B  
01.067 8(14)-Cedrene I No (lack of supporting data) B  
(01.003) (Pin-2(10)-ene) 
 
I No (lack of supporting data) B A 
(01.004) (Pin-2(3)-ene) 
 
I No (lack of supporting data) B A 
(01.007) (beta-Caryophyllene) I No (lack of supporting data) B A 
(01.009) (Camphene) 
 
I No (lack of supporting data) B A 
(01.017) (Valencene) I No (lack of supporting data) B A 
(01.024) (beta-Bourbonene) H
H H
I No (lack of supporting data) B A 
(01.026) (1(5),7(11)-Guaiadiene) I No (lack of supporting data) B A 
(01.029) (delta-3-Carene) 
 
I No (lack of supporting data) B A 
VI: MACROCYCLIC, NONAROMATIC HYDROCARBONS 
01.042 Germacra-1(10),4(14),5-triene I No (lack of supporting data) B  
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Table 4.1 Subgroups as classified by EFSA within the groups of the JECFA evaluated hydrocarbons (JECFA, 
2006a) and the EFSA evaluated hydrocarbons in FGE.25Rev2. The JECFA evaluated hydrocarbons are listed in 
brackets. 
FL-no EU Register name Structural formula Struc. 
class 
Predicted metabolism to 
innocuous products? 
(by EFSA) 
A- or B- 
side of the 
Procedure 
(EFSA) 
A- or B- 
side of the 
Procedure 
(JECFA) 
01.043 3,7,10-Humulatriene I No (lack of supporting data) B  
 
The Panel agrees with the application of the Procedure as performed by the JECFA for seven 
substances in the subgroup III (Cyclohexene hydrocarbons) and one substance in subgroup IVe (Alkyl 
substituted benzene hydrocarbons) [FL-no: 01.002, 01.005, 01.006, 01.016, 01.019, 01.020, 01.045 
and 01.077], which all are evaluated via the A-side of the Procedure with the conclusion “no safety 
concern at estimated levels of intake based on the MSDI approach”. 
For the remaining 16 substances, which were all predicted to be metabolised to innocuous products 
(evaluated via the A-side of the Procedure) by the JECFA, the Panel does not agree with the way the  
JECFA applied the Procedure for the evaluation of Flavouring Substances:  
For the two biphenyls in subgroup IVd (biphenyl [FL-no: 01.013] and 4-methyl-1,1-biphenyl [FL-no: 
01.011]), the JECFA considered a long-term carcinogenicity study in rats, which shows tumour related 
lesions in the bladder at doses of 4500 mg/kg bw/day in both sexes and tumours in males rats at this 
dose. The JECFA concluded that the induction of bladder tumours and tumour related lesions was 
secondary to the formation of bladder calculi. While this effect may be relevant for humans, it would 
be considered unlikely as the high doses necessary would not be applicable for human intakes and 
physiological differences between humans and rodents mean that humans are more likely to excrete 
bladder calculi and a NOEL of 25 mg/kg bw/day was derived from this study. However, the Panel 
concluded that the Procedure could not be applied for these two substances [FL-no: 01.011 and 
01.013] based on in vitro genotoxicity and carcinogenicity data available. For biphenyl [FL-no: 
01.013] the Panel concluded, due to concern with respect to in vitro genotoxicity (absence of valid in 
vivo genotoxicity) and unresolved problems with respect to carcinogenicity (especially development of 
bladder tumours in male rats), not to evaluate biphenyl [FL-no: 01.013] and the structurally related 4-
methyl-1,1-biphenyl [FL-no: 01.011] through the Procedure. This is in accordance with the 
conclusions in the Concise International Chemical Assessment Document 6 (CICAD, 1999) 
concerning potential genotoxicity and carcinogenicity of biphenyl: "The results of in vitro studies 
indicate that biphenyl has mutagenic potential; in the absence of reassurance from reliable results from 
in vivo tests, it is assumed that exposure to biphenyl may be associated with a mutagenic risk” and 
“However, 1) observations of an increased incidence of histopathological effects and the formation of 
calculi within the urinary bladder, in the absence of bladder tumours, in female rats administered 
biphenyl for 2 years, 2) a lack of data identifying a direct association between calculi formation, 
regenerative hyperplasia of the urothelium, and the development of bladder tumours within individual 
male animals, and 3) the potential genotoxicity of biphenyl could suggest that the development of 
bladder tumours in the male rats may not have been entirely due to effects associated with the 
formation of calculi within the urinary bladder. This observation, as well as evidence of 
hepatocarcinogenicity in female mice, raises some concerns with respect to the potential 
carcinogenicity of biphenyl” (CICAD, 1999).  
The Panel noted that the Joint Meeting of the FAO Working Party and the WHO Expert Committee on 
Pesticide Residues (FAO/WHO) has allocated an ADI of 0 - 0.125 mg/kg bw/day for biphenyl 
(FAO/WHO, 1967; JMPR, 1968). However, due to more recent studies on genotoxicity and 
carcinogenicity of biphenyl, the Panel has expressed concern with respect to the use of biphenyl as a 
flavouring substance (see above).  
Flavouring Group Evaluation 78, Revision 1
 
 
25 EFSA Journal 2011; 9(6):2178 
For four substances in subgroup II [FL-no: 01.008, 01.018, 01.040 and 01.061]: Acyclic alkenes, it 
could not be anticipated that the substances would be metabolised to innocuous products due to 
presence of terminal double bond, which may give rise to reactive metabolites without counteracting 
metabolic options. No adequate NOAEL was available, either for the JECFA or for the EFSA 
evaluated substances, to provide a margin of safety for the four substances at step B4, therefore 
additional data are required. 
For one substance in subgroup IVb: Naphthalene hydrocarbons, metabolism to toxic metabolites are 
known [FL-no: 01.014]. No adequate NOAEL was available, either for the JECFA or the EFSA 
evaluated substances, to provide a margin of safety for the substance at step B4, therefore additional 
data are required. 
For one substance (1-isopropenyl-4-methylbenzene, [FL-no: 01.010]) in subgroup IVe: Alkyl 
substituted benzenes, it could not be anticipated that the substance would be metabolised to innocuous 
products due to presence of terminal double bond which may give rise to reactive metabolites without 
counteracting metabolic options. In a 90 day study in rats by Posternak et al. (Posternak et al., 1969) 
NOAEL 0.625 mg/kg bw/day could be established. Compared to the MSDI of 18 
microgram/capita/day ~ 0.3 µg/kg bw/day, the NOAEL provides a margin of safety of 2000.  
For eight substances in subgroup V [FL-no: 01.003, 01.004, 01.007, 01.009, 01.017, 01.024, 01.026 
and 01.029]: Bi- and tricyclic, nonaromatic hydrocarbons, no data are available to conclude that the 
substances will be metabolised to innocuous products. No adequate NOAEL was available, either for 
the JECFA or the EFSA evaluated substances, to provide a margin of safety for the four substances at 
step B4, therefore additional data are required for these eight substances. 
However, for one substance [FL-no: 01.024] no European production figure was available and 
consequently no European exposure estimate could be calculated. Accordingly, the safety in use in 
Europe could not be assessed using the Procedure for this substance. 
5. Conclusion 
The Panel concluded that the 24 substances in the JECFA flavouring groups of aliphatic and alicyclic 
and aromatic hydrocarbons are structurally related to the group of 37 aliphatic and aromatic 
hydrocarbons evaluated by EFSA in the Flavouring Group Evaluation 25 (FGE.25).  
The Panel agrees with the application of the Procedure as performed by the JECFA for eight of the 24 
substances considered in this FGE [FL-no: 01.002, 01.005, 01.006, 01.016, 01.019, 01.020, 01.045 
and 01.077]. 
Two substances [FL-no: 01.011 and 01.013] are genotoxic in vitro and there are unresolved problems 
with potential carcinogenicity and therefore the Panel concluded that they cannot be evaluated using 
the Procedure. 
For the following 14 substances [FL-no: 01.003, 01.004, 01.007, 01.008, 01.009, 01.010, 01.014, 
01.017, 01.018, 01.024, 01.026, 01.029, 01.040 and 01.061] it cannot be concluded that they are 
metabolised to innocuous substances and therefore their evaluation should proceed along the B-side of 
the Procedure. For one of these substances, 1-isopropenyl-4-methylbenzene [FL-no: 01.010] from 
subgroup Ive (alkyl substituted benzene hydrocarbons), a NOAEL was available, giving an adequate 
margin of safety compared to the estimated level of intake. For 13 substances no applicable NOAEL is 
available for the substance itself or on a structurally related compound and therefore further data are 
required. 
For one substances [FL-no: 01.024] the JECFA evaluation is only based on MSDI values derived from 
production figure from the USA. EU production figure is needed in order to finalise the evaluation of 
this substance.  
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For two substances use levels have been provided by the Industry [FL-no: 01.008 and 01.026]. The 
mTAMDI figures calculated were above the threshold of concern for structural class I. For these two 
substances more reliable exposure data are needed. On the basis of such additional data these 
flavouring substances should be reconsidered using the Procedure. For the remaining 22 substances 
evaluated through the Procedure use levels are needed to calculate the mTAMDIs in order to identify 
those flavouring substances that need more refined exposure assessment to finalise the evaluation. 
In order to determine whether the conclusion for the 24 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity are available for 10 of the 24 JECFA 
evaluated substances. For two substances [FL-no: 01.018 and 01.061] information on the isomeric 
composition is lacking and for 14 substances [FL-no: 01.004, 01.007, 01.008, 01.009, 01.017, 01.018, 
01.019, 01.020, 01.024, 01.026, 01.029, 01.040, 01.045 and 01.061] further information on the 
composition of the mixture is requested.  
Thus, for 14 substances [FL-no: 01.004, 01.007, 01.008, 01.009, 01.017, 01.018, 01.019, 01.020, 
01.024, 01.026, 01.029, 01.040, 01.045 and 01.061] the Panel has reservations (no European 
production volumes available, preventing them from being evaluated using the Procedure, and/or 
missing information on stereoisomerism/composition of mixture). For two of the 24 JECFA evaluated 
substances the Procedure could not be applied [FL-no: 01.011 and 01.013] due to concern with respect 
to genotoxicity and carcinogenicity. For 13 of the 24 JECFA evaluated aliphatic, alicyclic and 
aromatic hydrocarbons [FL-no: 01.003, 01.004, 01.007, 01.008, 01.009, 01.014, 01.017, 01.018, 
01.024, 01.026, 01.029, 01.040 and 01.061] additional toxicity data are requested. For the remaining 
six substances [FL-no: 01.002, 01.005, 01.006, 01.010, 01.016 and 01.077] the Panel agrees with 
JECFA conclusion “no safety concern at estimated levels of intake as flavouring substances” based on 
the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY  
Table 1: specifications summary for the JECFA evaluated substances in the present group (JECFA, 2005b) 
Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005b) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
01.002 
1325 
1-Isopropyl-4-methylbenzene 
 
2356 
620 
99-87-6 
Liquid 
C10H14 
134.21 
Insoluble 
Soluble 
177 
 
IR 
97 % 
1.484-1.491 
0.853-0.855 
 
 
01.003 
1330 
Pin-2(10)-ene 2903 
2114 
127-91-3 
Liquid 
C10H16 
136.24 
Insoluble 
Insoluble 
163-166 
 
NMR 
97 % 
1.476-1.482 
0.867-0.871 
 
Racemate. 
01.004 
1329 
Pin-2(3)-ene 
 
2902 
2113 
80-56-8 
Liquid 
C10H16 
136.24 
Insoluble 
Soluble 
155 
 
NMR 
97 % 
1.462-1.468 
0.855-0.860 
 
Racemate.  
According to the JECFA: 
"Min. assay value may 
include traces of limonene, 
beta pinene and other 
common C10H16 terpenes". 
Composition of mixture to 
be specified. 
01.005 
1331 
Terpinolene 
 
3046 
2115 
586-62-9 
Liquid 
C10H16 
136.24 
Insoluble 
Insoluble 
183-185 
 
NMR 
95 % 
1.474-1.484 
0.872-0.882 
 
 
01.006 
1328 
alpha-Phellandrene 
 
2856 
2117 
99-83-2 
Liquid 
C10H16 
136.24 
Insoluble 
Soluble 
175 
 
IR 
95 % 
1.471-1.477 
0.845-0.855 
 
Racemate. 
01.007 
1324 
beta-Caryophyllene 
 
2252 
2118 
87-44-5 
Liquid 
C15H24 
204.36 
Insoluble 
Soluble 
256 
 
IR 
80 % 
1.498-1.504 
0.899-0.908 
 
CASrn refers to (1R,4E,9S)-
isomer. According to 
JECFA: Min. Assay value is 
"80 %" and secondary 
components "C15H24 terpene 
hydrocarbons (eg. 
Valencene)". 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005b) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
Composition of mixture to 
be specified. 
01.008 
1327 
Myrcene 
 
2762 
2197 
123-35-3 
Liquid 
C10H16 
136.24 
Insoluble 
Soluble 
166-167 
 
NMR 
90 % 
1.466-1.471 
0.789-1.793 
 
According to JECFA: Min. 
assay value is 90 % and 
secondary components 
"C15H24 terpene 
hydrocarbons (eg. 
Valencene); Min. assay may 
include traces of limonene, 
alpha and beta pinene and 
other common C10H16 
terpenes". 
Composition of mixture to 
be specified. 
01.009 
1323 
Camphene 
 
2229 
2227 
79-92-5 
Solid 
C10H16 
136.24 
Insoluble 
Soluble 
n.a. 
52 
NMR 
80 % 
n.a. 
n.a. 
 
Racemate.  
The JECFA: Min. assay 
value is 80 % and sec. 
comp. "C15H24 terpene 
hydrocarbons (Valencene); 
Min assay may incl traces of 
limonene, myrcene, alpha-
and beta-pinene and other 
common C10H16 terp".  
Composition of mixture to 
be specified.  
01.010 
1333 
1-Isopropenyl-4-methylbenzene 
 
3144 
2260 
1195-32-0 
Liquid 
C10H12 
132.20 
Insoluble 
Soluble 
186-189 
 
NMR 
97 % 
1.532-1.535 
0.846-0.854 
 
 
01.011 
1334 
4-Methyl-1,1'-biphenyl 
 
3186 
2292 
644-08-6 
Solid 
C13H12 
168.24 
Insoluble 
Soluble 
n.a. 
49-50 
NMR 
98 % 
n.a. 
n.a. 
 
 
01.013 
1332 
Biphenyl 
 
3129 
10978 
92-52-4 
Solid 
C12H10 
154.21 
Insoluble 
Soluble 
254 
69 
NMR 
99 % 
n.a. 
n.a. 
 
 
01.014 
1335 
1-Methylnaphthalene 
 
3193 
11009 
90-12-0 
Liquid 
C11H10 
142.20 
Insoluble 
Soluble 
241-245 
 
NMR 
97 % 
1.612-1.618 
1.020-1.025 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005b) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
01.016 
1336 
1,4(8),12-Bisabolatriene 3331 
10979 
495-62-5 
Liquid 
C15H24 
204.36 
Insoluble 
Insoluble 
262 
 
NMR 
97 % 
1.493-1.497 
0.850-0.858 
 
 
01.017 
1337 
Valencene 
 
3443 
11030 
4630-07-3 
Liquid 
C15H24 
204.36 
Insoluble 
Insoluble 
123 (14 hPa) 
 
NMR 
94 % 
1.498-1.508 
0.914-0.919 
 
CASrn refers to (+)-
Valencene.  
According to the  JECFA: 
Min. assay value is "94 %" 
and secondary components 
"Other sesquiterpenes".  
Composition of mixture to 
be specified. 
01.018 
1338 
beta-Ocimene   6) 
(E, E)- isomer shown  
3539 
11015 
13877-91-3 
Liquid 
C10H16 
136.24 
Insoluble 
Soluble 
177 
 
NMR 
80 % 
1.478-1.491 
0.801-0.805 
 
CASrn in Register does not 
specify stereoisomeric 
composition. 
Composition of mixture to 
be specified. 
01.019 
1339 
alpha-Terpinene 
 
3558 
11023 
99-86-5 
Liquid 
C10H16 
136.24 
Insoluble 
Soluble 
173 
 
NMR 
89 % 
1.475-1.480 
0.833-0.838 
 
According to the JECFA: 
Min. assay value is "89 %" 
and secondary components 
"1,4- and 1,8-cineole; 
Minimum assay value may 
include traces of limonene, 
alpha- and beta-pinene and 
other common C10H16 
terpenes". 
Composition of mixture to 
be specified. 
01.020 
1340 
gamma-Terpinene 
 
3559 
11025 
99-85-4 
Liquid 
C10H16 
136.24 
Insoluble 
Soluble 
182 
 
NMR 
95 % 
1.472-1.478 
0.841-0.845 
 
According to JECFA: Min. 
assay value is "95 %" and 
"may include traces of 
limonene, alpha and beta- 
pinene and other common 
C10H16 terpenes". 
Composition of mixture to 
be specified. 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005b) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
01.024 
1345 
beta-Bourbonene H
H H
 
 
11931 
5208-59-3 
Liquid 
C15H24 
204.36 
Insoluble 
Soluble 
121 (14 hPa) 
 
NMR 
96 % 
1.500-1.507 
0.899-0.908 
 
Stereoisomeric composition 
specified by CASrn and 
name in Register. According 
to JECFA: Min. assay value 
is "96 %" and "may include 
traces of other C15H24 
compounds (cadinene, 
guaiene, farnesene)". 
Composition of mixture to 
be specified. 
01.026 
1347 
1(5),7(11)-Guaiadiene 
S
S
 
 
 
88-84-6 
Liquid 
C15H24 
204.36 
Insoluble 
Soluble 
118 (3 hPa) 
 
NMR 
96 % 
1.503-1.509 
0.912-0.918 
 
Stereoisomeric composition 
specified by CASrn and 
name in Register.  
According to the JECFA: 
Min. assay value is "96 %" 
and "may include traces of 
other C15H24 compounds 
(cadinene, farnesene, 
valencene)". 
Composition of mixture to 
be specified. 
01.029 
1342 
delta-3-Carene 
 
3821 
10983 
13466-78-9 
Liquid 
C10H16 
136.24 
Insoluble 
Slightly soluble 
169-174 
 
NMR 
92 % 
1.468-1.478 
0.860-0.868 
 
Racemate. 
According to JECFA: Min. 
Assay value is "92 %" and 
secondary components 
"beta-pinene, limonene, 
myrcene, p-cymene". 
Composition of mixture to 
be specified. 
01.040 
1343 
alpha-Farnesene 
 
3839 
10998 
502-61-4 
Liquid 
C15H24 
204.36 
Insoluble 
Slightly soluble 
53-57 (1 hPa) 
 
NMR 
67 % 
1.490-1.500 
0.834-0.845 
 
CASrn & name in Register: 
(E,E).   
According to the  JECFA: 
Min. assay value is "38 % 
alpha + 29 % beta (sum of 
E/Z isomers)" and sec.comp. 
"bisabolene, up to 10 % 
other isomers (valencene, 
bourbonene, cadinene, 
guaiene)". 
Composition of mixture to 
be specified. 
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Table 1: Specification Summary of the Substances in the JECFA Flavouring Group of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005b) 
FL-no 
JECFA-
no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
EFSA comments 
01.045 
1326 
d-Limonene 
 
2633 
491 
5989-27-5 
Liquid 
C10H16 
136.24 
Insoluble 
Soluble 
175-177 
 
IR 
96 % 
1.471-1.477 
0.838-0.843 
 
According to the JECFA: 
Min. assay value is "96 % 
(sum of d/l isomers)" and 
"Compounds present above 
0.5 %: linalool, myrcene". 
Composition of mixture to 
be specified. 
01.061 
1341 
Undeca-1,3,5-triene   6)  3795 
 
16356-11-9 
Liquid 
C11H18 
150.26 
Slightly soluble 
Soluble 
80-81 (16 hPa) 
 
NMR 
94 % 
1.510-1.518 
0.788-0.796 
 
According to JECFA: Min. 
assay value is "94 % (sum of 
cis/trans isomers)" and 
secondary components 
"2,4,6-undecatriene (Z,Z,E)" 
CASrn in Register does not 
specify stereoisomers. 
Composition of mixture to 
be specified. 
01.077 
1344 
1-Methyl-1,3-cyclohexadiene 
 
 
 
1489-56-1 
Liquid 
C7H10 
94.16 
Insoluble 
Soluble 
118-120 
 
NMR 
95 % 
1.446-1.452 
0.846-0.853 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
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TABLE 2: GENOTOXICITY DATA  
Table 2.1: Genotoxicity Data (in vitro / in vivo) for 19 Aliphatic, Alicyclic Hydrocarbons (JECFA, 2006a)  
Table 2.1: Summary of Genotoxicity Data of 19 Aliphatic, Alicyclic Hydrocarbons  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vitro 
01.009 
1323 
Camphene  
  
Reverse mutation  S. typhimurium  
TA98, TA100  
0.05–100 μl/plate  
(42.1–84,200 μg/plate)1  
Negativeb  (Rockwell and Raw, 1979) 
Reverse mutation  S. typhimurium  
TA98, TA100,  
UTH8413, UTH8414  
10–1000 μg/plate  Negativec  (Connor et al., 1985) 
Sister chromatid  
exchange  
Chinese hamster  
ovary K-1 cells  
10–1000 μmol/l  
(1.4–136.2 μg/ml)d,e  
Negativef  (Sasaki et al., 1989) 
01.007 
1324 
beta-Caryophyllene  
  
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537, TA1538  
0.1–150 μl/plate  
(90.4–135 525 μg/plate)g  
Negativec  (Jagannath, 1984b) 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537, TA1538  
Up to 150 000 μg/plate  Negativec  (Heck et al., 1989) 
Reverse mutation  S. typhimurium  
TA97, TA98, TA100,  
TA1535  
3.3–333 μg/plate -S9h  
1–10 000 μg/plate +S9h  
Negativec  (NTP, 2004b) 
Sister chromatid  
exchange  
Chinese hamster  
ovary K-1 cells  
10–1000 μmol/l  
(2.0–204.4 μg/ml)i,e  
Negativef  (Sasaki et al., 1989) 
Unscheduled  
DNA synthesis  
Rat hepatocytes  Up to 10 000 μg/ml  Negative  (Heck et al., 1989) 
01.045 
1326 
d-Limonene  
  
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537  
0.03–30 μmol/plate  
(4.1–4087 μg/plate)k,l  
Negativec  (Florin et al., 1980) 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537  
0.3–33 μg/plate -S9;  
10–3333 μg/plate +S9  
Negativec  (Haworth et al., 1983; NTP, 
1990e) 
Reverse mutation  S. typhimurium  
TA98, TA100,  
UTH8413, UTH8414  
10–500 μg/plate  Negativec  (Connor et al., 1985) 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537, TA1538  
Up to 150 000 μg/plate  Negativec  (Heck et al., 1989) 
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Table 2.1: Summary of Genotoxicity Data of 19 Aliphatic, Alicyclic Hydrocarbons  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
Reverse mutation  S. typhimurium  
TA102  
Up to 5 000 μg/plate  Negativeb  (Müller et al., 1993) 
Forward mutation,  
(non-)reciprocal  
recombination  
Saccharomyces  
cerevisiae MP1  
Up to 230 mmol/l  
(31 335 μg/ml)k  
Negativef  (Fahrig, 1984) 
Forward mutation  Mouse lymphoma  
L5178Y Tk+/- cells  
Up to 100 μg/ml  Negativec  (Heck et al., 1989) 
Forward mutation  Mouse lymphoma  
L5178Y Tk+/- cells  
Up to 100 μg/mlm  Negativec  (Myhr et al., 1990; NTP, 
1990e) 
Sister chromatid  
exchange  
Chinese hamster  
ovary K-1 cells  
10–333 μmol/l  
(1.4–45.4 μg/ml)k,e  
Negativef  (Sasaki et al., 1989) 
Sister chromatid  
exchange  
Chinese hamster  
ovary cells  
15–162 μg/ml -S9;  
16.2–162 μg/ml +S9  
Negativec  (Anderson et al., 1990; NTP, 
1990e) 
Chromosomal  
aberration  
Chinese hamster  
ovary cells  
10–100 μg/ml -S9;  
50–500 μg/ml +S9  
Negativec  (Anderson et al., 1990; NTP, 
1990e) 
Cell  
transformation  
Syrian hamster  
embryo cells  
0.1–100 μg/ml  Negative  (Pienta, 1980) 
Cell  
transformation  
Syrian hamster  
embryo cells  
0.1–3 mmol/l  
(13.6–408.7 μg/ml)k  
Positiven  (Rivedal et al., 2000) 
01.008 
1327 
Myrcene 
 
Reverse mutation  S. typhimurium  
TA97, TA98,  
TA100, TA1535  
33–3 333 μg/plate -S9o;  
33–10 000 μg/plate +S9o  
Negativec  (NTP, 2004c) 
Gene mutation  Chinese hamster  
V79 Hprt cells  
100–1 000 μg/ml  Negativec  (Kauderer et al., 1991) 
Sister chromatid  
exchange  
Human  
lymphocytes  
100–1 000 μg/ml  Negativec  (Kauderer et al., 1991) 
Sister chromatid  
exchange  
Chinese hamster  
V79 cells  
100–500 μg/ml -S9;  
500 μg/ml +S9  
Negativec  (Röscheisen et al., 1991) 
Sister chromatid  
exchange  
Hepatic tumour  
cells  
100–500 μg/ml  Negativep  (Röscheisen et al., 1991) 
Chromosomal  
aberration  
Human  
lymphocytes  
100–1 000 μg/ml  Negativec  (Kauderer et al., 1991) 
01.006 
1328 
alpha-Phellandrene 
 
Sister chromatid  
exchange  
Chinese hamster  
ovary K-1 cells  
33.3–1 000 μmol/l  
(4.5–136.2 μg/ml)q  
Negativef  (Sasaki et al., 1989) 
01.004 
1329 
Pin-2(3)-ene 
 
Reverse mutation  S. typhimurium  
TA98, TA100  
0.05–100 μl/plate  
(43–85 920 μg/plate)r  
Negativeb  (Rockwell and Raw, 1979) 
Reverse mutation  S. typhimurium  
TA98, TA100,  
TA1535, TA1537  
0.03–30 μmol/plate  
(4.1–4 087 μg/plate)s,l  
Negativec  (Florin et al., 1980) 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535, TA1537, 
0.1–25 μl/plate  
(85.9–21 480 μg/plate)r,t  
Negativec  (Jagannath, 1984a) 
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Table 2.1: Summary of Genotoxicity Data of 19 Aliphatic, Alicyclic Hydrocarbons  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
TA1538  
Reverse mutation  S. typhimurium  
TA98, TA100,  
UTH8413, UTH8414  
10–500 μg/plate  Negativec  (Connor et al., 1985) 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537, TA1538  
Up to 25 000 μg/plate  Negativec  (Heck et al., 1989) 
Unscheduled  
DNA synthesis  
Rat hepatocytes  Up to 10 000 μg/ml  Negative  (Heck et al., 1989) 
01.003 
1330 
Pin-2(10)-ene 
 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537  
0.03–30 μmol/plate  
(4.1–4 087 μg/plate)u,v  
Negativec  (Florin et al., 1980) 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537, TA1538  
0.01–5 μl/plate  
(8.6–4 320 μg/plate)w,x  
Negativec  (DeGraff, 1983a) 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537, TA1538  
Up to 5 000 μg/plate  Negativec  (Heck et al., 1989) 
Sister chromatid  
exchange  
Chinese hamster  
ovary K-1 cells  
33.3–1 000 μmol/l  
(4.5–136.2 μg/ml)u  
Negativef  (Sasaki et al., 1989) 
01.020 
1340 
gamma-Terpinene 
 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537, TA1538  
Up to 50 000 μg/plate  Negativec  (Heck et al., 1989) 
Unscheduled  
DNA synthesis  
Rat hepatocytes  Up to 30 μg/ml  Negative  (Heck et al., 1989) 
01.029 
1342 
delta-3-Carene 
 
Reverse mutation  S. typhimurium  
TA98, TA100, TA102  
1.25–5 μl/plate  
(1 078–4 314 μg/plate)y  
Positivez  (Kurttio et al., 1990) 
1346 Cadinene, not in Register  Reverse mutation  S. typhimurium  
TA97, TA98, TA100,  
TA1535, TA1537  
1–100 μg/plate -S91;  
100–10 000 μg/plate +S91  
Negative;  
Positive2  
(NTP, 2004d) 
Reverse mutation  S. typhimurium  
TA98, TA100, 
TA1535,  
TA1537  
10–3 333 μg/plate -S9;  
100–10 000 μg/plate +S9o  
Negativec  (Haworth et al., 1983; NTP, 
2004e) 
Forward mutation  Mouse lymphoma  
L5178Y Tk+/- cells  
0.005–0.05 μg/ml -S9  
(4.6–46.2 μg/ml)4,5;  
0.01–0.08 μl/ml +S9  
(9.2–73.9 μg/ml)4,6  
Negativec  (NTP, 2004f) 
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Table 2.1: Summary of Genotoxicity Data of 19 Aliphatic, Alicyclic Hydrocarbons  
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
Sister chromatid  
exchange  
Chinese  
hamster ovary cells  
8.9–26.6 μg/ml -S9;  
22.2–31.1 μg/ml +S9  
Equivocal;  
Negative  
(NTP, 2004g) 
Chromosomal  
aberration  
Chinese hamster  
ovary cells  
24.9–35.5 μg/ml -S9;  
30.2–40 μg/ml +S9  
Negativec  (NTP, 2004g) 
In vivo 
01.045 
1326 
d-Limonene 
 
Mammalian spot  
test  
Mouse (C57BLxT)  
embryos  
215 mg/kg bw7  Negative  (Fahrig, 1984) 
01.008 
1327 
Myrcene Chromosomal  
aberration  
Rat bone  
marrow cells  
100–1 000 mg/kg bw8  Negative9  (Zamith et al., 1993) 
   Micronucleus  
formation  
Mouse  
peripheral blood  
250–2 000 mg/kg bw10  Negative  (NTP, 2004h) 
a Calculated using a density of camphene of 0.842 g/ml (Lewis, 1999). 
b With metabolic activation. 
c With and without metabolic activation. 
d Calculated using relative molecular mass of camphene of 136.24. 
e Cytotoxicity observed at the highest dose/concentration tested. 
f Without metabolic activation. 
g Calculated using a density of β-caryophyllene of 0.9035 (0.897–0.910) g/ml (Lewis, 1999). 
h Precipitation or slight toxicity was occasionally observed at the higher concentrations tested. 
i Calculated using relative molecular mass of β-caryophyllene of 204.36. 
j Isomer not specified. 
k Calculated using relative molecular mass of d-limonene of 136.24. 
l Cytotoxicity and precipitation observed at doses >3 μmol/plate. 
m In some trials concentrations ≥50 μg/ml were lethal. 
n Although not statistically significant (p = 0.089), a fourfold increase in transformation frequency was observed. 
o Slight toxicity was occasionally observed at the highest concentration tested. 
p Slight increase in sister chromatid exchanges, which was reproducible but not dose-dependent. 
q Calculated using relative molecular mass of α-phellandrene of 136.24. 
r Calculated using a density of α-pinene of 0.8592 g/ml (Lewis, 1999). 
s Calculated using relative molecular mass of a-pinene of 136.24. 
t Cytotoxicity observed at doses of 2.5 to 25 μg/plate, depending on the different tester strains. 
u Calculated using relative molecular mass of β-pinene of 136.24. 
v Cytotoxicity observed at doses >3 μmol/plate. 
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w Calculated using a density of β-pinene of 0.864 g/ml (Lewis, 1999). 
x Cytotoxicity observed at doses of 2.5 to 5 μl/plate, depending on the different tester strains. 
y Calculated using a density of δ-3-carene of 0.8627 (0.8586–0.8668) g/ml (Merck, 1996). 
z Positive without metabolic activation in TA100 and TA102 at doses ≥2.5 μl/plate; negative with metabolic activation in all strains. 
1. Slight toxicity was observed at various doses. 
2. Equivocal/weak positive only in TA97 and TA100 with metabolic activation. 
3. β-Cadinene was tested. 
4. Calculated using a density of β-cadinene of 0.9239 g/ml (Merck, 1996). 
5. The highest concentration of 0.05 μl/ml was lethal. 
6. In some trials, concentrations ≥ 0.04 μl/ml were lethal. 
7. Administered via injection into the peritoneal cavity of the dam. 
8. Administered via gavage. 
9. A dose-related increase in mitotic index was observed, but no clastogenicity. 
10. Administered via gavage for 90 days. 
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Table 2.2: Genotoxicity Data (in vitro / in vivo) for Five Aromatic Hydrocarbons (JECFA, 2006a)  
Table 2.2: Summary of Genotoxicity Data of Five Aromatic Hydrocarbons 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
01.002 
1325 
1-Isopropyl-4-methylbenzene Reverse mutation  S. typhimurium  
TA98, TA100  
0.05–100 μl/plate  
(42.7–85 300 μg/  
plate)a  
Negativeb  (Rockwell and Raw, 1979) 
01.013 
1332 
Biphenyl  
 
  
Reverse mutation  S. typhimurium TA98,  
TA1535, TA1537, 
TA1538  
10–10 000 μg/plated  Negativee  (Clark et al., 1977) 
Reverse mutation  S. typhimurium TA98,  
TA100, TA1535, 
TA1538  
4–2500 μg/plate  Negativeb  (Anderson and Styles, 1978) 
Reverse mutation  S. typhimurium TA98,  
TA100, TA1535, 
TA1537, TA1538  
1–10 000 μg/plate  Negativee  (Clark et al., 1979) 
Reverse mutation  S. typhimurium TA98,  
TA100  
1–100 μg/plate  Negativee  (Hirayama et al., 1981) 
Reverse mutationf  S. typhimurium G46,  
TA98, TA100, TA1535,  
TA1537, TA1538, 
C3076,  
D3052; Escherichia coli  
WP2 and WP2uvrA- 
NRg  Negativee  (Probst et al., 1981) 
Reverse mutation  S. typhimurium TA98,  
TA100, TA1535, 
TA1537  
1–100 μg/plateh  Negativee  (Haworth et al., 1983; NTP, 
2004i; NTP, 2004j) 
Reverse mutation  S. typhimurium TA98,  
TA100, TA1532, 
TA1535, TA1537, 
TA1538, TA2636  
0.1–500 μg/platei  Negativee  (Pagano et al., 1983) 
Reverse mutation  S. typhimurium TA98,  
TA100, TA2637  
10–5000 μg/platej  Negativee  (Nohmi et al., 1985) 
Reverse mutation  S. typhimurium  
TA97, TA98, TA100  
1–100 μg/plate  Negativee  (Brams et al., 1987) 
Reverse mutation  S. typhimurium TA98,  
TA100  
≤2000 μg/plate  Negativee  (Houk et al., 1989) 
SOS induction  Escherichia coli  2.4–154 μg/ml  Negativee  (Brams et al., 1987) 
DNA repair  E. coli WP2, WP2uvrA, 
CM571,  
WP100  
4000 μg/disc  Negative  (Hirayama et al., 1981) 
Mitotic recombination,  
gene conversion,  
Saccharomyces 
cerevisiae  
≤1 mmol/l  
plate)a (154 μg/ml)k  
Positivee  (Pagano et al., 1983) 
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Table 2.2: Summary of Genotoxicity Data of Five Aromatic Hydrocarbons 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
reversion  D7  
Forward mutation  Mouse lymphoma 
L5178Y  
Tk+/- cells  
98.7–395 μmol/l -S9  
(15.2–60.9 μg/ml)k,l;  
5.01–60 μmol/l +S9  
(0.8–9.3 μg/ml)k,m  
Positiven;  
Positiveo  
(Wangenheim and Bolcsfoldi, 
1988) 
Sister chromatid  
exchange  
Chinese hamster Don 
cells  
0.1–1 mmol/l  
(15.4–154 μg/ml)k  
Negativep,q  (Abe & Sasaki, 1977) 
Chromosomal aberration  Chinese hamster Don 
cells  
0.1–1 mmol/l  
(15.4–154 μg/ml)k  
Negativep  (Abe & Sasaki, 1977) 
Unscheduled DNA  
synthesis  
Rat hepatocytes  0.01–1000 μmol/l  
(0.002–154 μg/ml)k  
Negative  (Brouns et al., 1979) 
Unscheduled DNA  
synthesis  
Rat hepatocytes  0.5–1000 nmol/ml  
(0.08–154 μg/ml)k,r  
Negative  (Probst et al., 1981) 
Unscheduled DNA  
synthesis  
Rat hepatocytes  0.1–100 μmol/l  
(0.02–15.4 μg/ml)k  
Negative  (Hsia et al., 1983) 
01.011 
1334 
4-Methyl-1,1'-biphenyl Reverse mutation  S. typhimurium TA97,  
TA98, TA100, TA1535  
0.1–10 μg/plate -S9h; 
10–1000 μg/plate +S9h 
Negativee  (Zeiger et al., 1992) 
01.014 
1335 
1-Methylnaphthalene 
 
Reverse mutation  S. typhimurium TA98,  
TA100, TA1535, 
TA1537  
0.03–30 μmol/plate 
(4.3–4266 μg/plate)t,u 
Negativee  (Florin et al., 1980) 
Reverse mutation  S. typhimurium TA97,  
TA98, TA100, TA1535  
0.3–33 μg/plate -S9h;  
1–100 μg/plate +S9  
Negativee  (NTP, 2004k) 
a Calculated using a density of p-cymene of 0.853 g/ml (Lewis, 1999). 
b With metabolic activation. 
c Dowtherm A, a mixture of diphenyl (26 %) and diphenyl oxide (72 %), was tested. 
d Cytotoxicity observed at the highest dose/concentration tested. 
e With and without metabolic activation. 
f Modified Ames test. 
g NR, not reported. 
h Slight toxicity was occasionally observed at the highest concentration tested. 
i Cytotoxicity observed at doses of 50 to 100 μg/plate, depending on the different tester strains. 
j Lethality observed at doses of 2000 to 5000 μg/plate. 
k Calculated using the relative molecular mass of biphenyl of 154.21. 
l Cytotoxicity observed at 395 μmol/l (6 % cell viability), while 345 μmol/l is near-leathal concentration (14 % cell viability). 
m 40 and 60 μmol/l are near-lethal concentrations (12 - 15 % cell viability). 
n A significant increase in mutation frequency was noted at 296 - 395 μmol/l (with a twofold increase only at 395 μmol/l), but not at 
98.7 - 197 μmol/l. 
o Significant increase in mutation frequency was noted at 20–60 μmol/l (with an increase of more than twofold only at 40 and 60 μmol/l), but not 
at 5.01–10 μmol/l. 
p Without metabolic activation. 
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q Significant increase in induction of sister chromatid exchange was noted, but the increase was not dose-dependent and was less than twice the 
control value. At the highest concentration (1 mmol/l), the mitotic index was decreased to > 50 % of that for controls. 
r Cytotoxicity observed at concentrations > 100 nmol/ml. 
s Mixed isomers of methylbiphenyl tested. 
t Calculated using the relative molecular mass of 1-methylnaphthalene of 142.20. 
u Cytotoxicity observed at doses >3 μmol/plate. 
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Table 2.3: Genotoxicity Data (in vitro) EFSA / FGE.25Rev2 
In vitro mutagenicity/genotoxicity data are available for six candidate substances of the present flavouring group evaluation, for 11 supporting substances 
evaluated by the JECFA at the 63rd meeting and for two separate stereoisomers and for one structurally related non-Register substance (2-Methylbuta-1,3-
diene). Substances listed in brackets are the JECFA evaluated supporting substances in FGE.25Rev2 
Table 2.3: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
Cedrene washed6 
[CAS no 11028-42-5] 
Ames test S. typhimurium  
TA97, TA98; TA100; TA1535; TA102 
8-50004 Negative1 (Gocke, 1999b) Validity cannot be evaluated as substance is not 
specified. 
Cedarwood oil terpenes and tertonoids. 
Ames test S. typhimurium  
TA97, TA98; TA100; TA1535; TA102 
1.6-10005 Negative1 (Gocke, 1999b) Validity cannot be evaluated as substance is not 
specified. 
Cedarwood oil terpenes and tertonoids. 
Longifolene [1.047] Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537, 
TA102 
1-5000 Negative1 (Sokolowski, 2001)  
Dodecane [01.038] Ames test S. typhimurium  
TA98; TA100 
NR Negative1 (Tummey et al., 1992) 
 
Only part of abstract available. Validity of the 
study cannot be evaluated due to insufficient 
report of experimental details and results. 
Mammalian cell gene mutation test 
(mouse lymphoma assay) 
Mouse lymphocytes NR Negative1 (Tummey et al., 1992) 
 
Only part of abstract available. Validity of the 
study cannot be evaluated due to insufficient 
report of experimental details and results. 
Mammalian cell gene mutation test V79 Chinese hamster ovary cells 0.12 mM (20 µg/ml) Negative3 (Lankas et al., 1978) 
 
Published non-GLP study. Some important 
details of study design and results are not 
reported. Thus, the validity of the study cannot 
be evaluated. Study designed to evaluate the 
ability of various alkanes to enhance the 
mutagenicity induced by the chemical 
carcinogen methylazoxymethanol acetate. 
Dodecane showed no mutagenic activity per se, 
but increased the mutagenesis induced by 
pretreatment with the carcinogen. 
Tetradecane [01.057] Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
50, 150, 500, 1500, 5000 
µg/plate 
Negative1 (PETRESA, 19??a) 
 
(Study carried out by Huntingdon Research 
Centre, Report PEQ 5C/85914, sponsored by 
PETRESA; year not indicated). 
Unpublished GLP-study carried out in 
accordance with OECD guideline 471 as stated 
in the IUCLID datasheet submitted. IUCLID 
abstract available only. Validity of the study 
cannot be evaluated. 
Mammalian cell gene mutation test V79 Chinese hamster ovary cells 0.12 mM (23 µg/ml) Negative3 (Lankas et al., 1978) 
 
Published non-GLP study. Some important 
details of study design and results are not 
reported. Thus, the validity of the study cannot 
be evaluated. Study designed to evaluate the 
ability of various alkanes to enhance the 
mutagenicity induced by the chemical 
carcinogen methylazoxymethanol acetate. 
Tetradecane showed no mutagenic activity per 
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Table 2.3: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
se, but increased the mutagenesis induced by 
pretreatment with the carcinogen.  
Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; UTH8414; UTH8413 
0, 50, 100, 500, 1000, 
2000 µg/plate 
Negative1 (Conner et al., 1985)  
 
Published non-GLP study with insufficient 
report of some details of method and results. 
Thus, the validity of the study cannot be 
evaluated. Cytotoxicity not reported. 
Dodec-1-ene [01.037] Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538  
E. coli WP2uvrA 
0.2 to 2000 µg/plate Negative1 (Dean, 1980) 
 
Unpublished GLP-study. IUCLID abstract 
available only. Details of study design and 
results are not reported. Thus, the validity of the 
study cannot be evaluated. 
(2-Methylbuta-1,3-diene) Ames test S. typhimurium  
TA98; TA100; TA1530; TA1535; 
TA1538 
25% atmosphere 
concentration 
Negative1 (De Meester et al., 
1981) 
 
Published non-GLP study not in accordance 
with OECD guideline 471. Part of a larger study 
evaluating the effects of various experimental 
conditions (different liver cell preparations and 
concentrations) on the mutagenic activity of 
butadiene, hexachlorobutadiene and isoprene. 
Some important details of study design and 
results are not reported. Thus, the validity of the 
study cannot be evaluated. Plates were exposed 
to a 25 % 2-methylbuta-1,3-diene atmosphere 
for 24 hours.  
Ames test 
(preincubation method) 
S. typhimurium   
TA98; TA100; TA1535; TA1537 
0, 100, 333, 1000, 3333, 
10000 µg/plate 
Negative1 (Mortelmans et al., 
1986) 
(NTP, 1999d) 
Published summary report including detailed 
results from studies on 270 compounds tested in 
various laboratories within the NTP to a large 
extent in accordance with OECD guideline 471. 
Ames test S. typhimurium   
TA102; TA104 
NR Negative (Kushi et al., 1985) 
 
Published abstract only, of which part of the text 
including results is missing. No information on 
the use of a metabolic activation system. 
Validity of the study cannot be evaluated. 
Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535 
E. coli WP2uvrA/pKM101 
0, 500, 1000, 2000, 5000 
μg/plate 
Negative1 (Madhusree et al., 
2002) 
Published non-GLP study  with limited report of 
experimental details and results. Thus, the 
validity of the study cannot be evaluated. 
Sister chromatid exchange test Chinese hamster ovary cells 0, 50, 160, 500, 1600 
μg/ml (-S9)  
0, 160, 500, 1600, 5000 
μg/ml (+S9). 
Negative1 (NTP, 1999d; 
Galloway et al., 1987a) 
Published summary report including detailed 
results from studies on 108 chemicals tested 
within the NTP to a large extent in accordance 
with OECD guideline 479. 
Chromosomal aberration assay Chinese hamster ovary cells 0, 1600, 3000, 5000 
μg/ml 
Negative1 (NTP, 1999d; 
Galloway et al., 1987a) 
 
Published summary report including detailed 
results from studies on 108 chemicals tested 
within the NTP to a large extent in accordance 
with OECD guideline 473. 
(Myrcene [01.008]) Chromosomal aberration assay Human lymphocytes 100 - 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Mammalian cell gene mutation 
assay 
Chinese hamster ovary V79 cells 100 - 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Sister chromatid exchange test Human lymphocytes 100 - 1000 µg/ml Negative1 (Kauderer et al., 1991) 
 
Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Sister chromatid exchange test Chinese hamster ovary cells and hepatic 
tumour cell line 
100 - 500 µg/ml Negative1 (Röscheisen et al., 
1991) 
 
Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
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Table 2.3: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
Ames test 
(plate incorporation method) 
S. typhimurium TA97a ; TA98; TA100; 
TA1535 
Up to 1500 µg/plate 
(16 concentrations) 
Negative (Gomes-Carneiro et al., 
2005a) 
Valid studies which were carried out with a 
selection of 6 of the the concentrations 
mentioned. In the first run concentrations up to 
cytotoxicity were studied; in a second run only 
non-toxic concentrations were tested. 
Ames S. typhimurium TA97; TA98; TA100; 
TA1535 
10 – 10 000 µg/plate Negative1 (NTP, 2010b)  
Reverse mutation E. coli WP2uvrA/pKM101 50 – 10 000 µg/plate Negative1 (NTP, 2010b)  
Ames S. typhimurium TA97a; TA98; TA100; 
TA1535 
10 - 5000 Negative1 (Gomes-Carneiro et al., 
2005a) 
 
Ames S. typhimurium TA97a; TA98; TA100; 
TA1535 
1 - 1500 Negative1 (Gomes-Carneiro et al., 
2005a) 
 
(d-Limonene [01.045]) Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.1, 41, 410, 4100 
µg/plate) 
Negative1 (Florin et al., 1980) 
 
Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
150,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA102 5000 µg/plate Negative1 (Müller et al., 1993) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537 
3333 µg/plate Negative1 (Haworth et al., 1983) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test 
(preincubation method)  
S. typhimurium   
TA98; TA100, UTH8414 and UTH8413 
0, 10 to 500 µg/plate  
(5 concentrations) 
Negative1 (Conner et al., 1985) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Forward mutation assay L5178Y Mouse  
lymphoma 
Up to 100 µg/ml Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Forward mutation assay L5178Y Mouse Lymphoma Up to 100 nl/ml  
 
Negative1 (Myhr et al., 1990) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Chromosomal aberration assay Chinese hamster  
ovary cells 
Up to 500 µg/ml Negative1 (Anderson et al., 1990) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Sister chromatid exchange test Chinese hamster ovary cells Up to 162 µg/ml Negative1 (Anderson et al., 1990) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Sister chromatid exchange test Chinese hamster ovary cells 10 - 333 µmol/ml 
(1.4 - 45.4 µg/ml). 
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
(gamma-Terpinene [01.020]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Uo to 50,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Unscheduled DNA synthesis Rat hepatocytes Uo to 30 µg/ml Negative (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
(alpha-Terpinene [01.019]) Ames test 
(plate incorporation method) 
S. typhimurium TA97a ; TA98; TA100; 
TA1535 
Up to 1500 µg/plate 
(13 concentrations) 
Negative (Gomes-Carneiro et al., 
2005a) 
Valid studies which were carried out with a 
selection of 6 of the the concentrations 
mentioned. In the first run concentrations up to 
cytotoxicity were studied; in a second run only 
non-toxic concentrations were tested. 
(alpha–Phellandrene [01.006]) Sister chromatid exchange test Chinese hamster ovary cells Uo to 1000 µM(136.2 
µg/ml) 
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
(delta-3-Carene [01.029])  Ames test 
(plate incorporation method) 
S. typhimurium TA98; TA100; TA102 Up to 5 µl/plate  
(up to 4300 µg/plate; 5 
concentrations) 
Positive3 
Negative2 
(Kurttio et al., 1990) Published non-GLP study with insufficiently 
reported results. Limited validity. Positive 
without metabolic activation in TA100 and 
TA102 and at doses of 2.5 μl/plate and higher. 
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Table 2.3: GENOTOXICITY (in vitro) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(Pin-2(3)-ene [01.004]) 
 
 
Ames test S. typhimurium  
TA98; TA100 
Up to 100 µl/plate 
(85,800 µg/ plate) 
Negative2 (Rockwell and Raw, 
1979) 
Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537 
0.03, 0.3, 3, 30 µM/plate  
(4.1, 41, 410, 4100 µg/ 
plate) 
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Up to 25000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Up to 25 µl/plate 
(21,450 µg/ plate) 
Negative1 (Jagannath, 1984a) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA98; TA100; 
UTH8413; UTH8414 
0, 10 to 500 µg/plate  
(5 concentrations) 
Negative1 (Conner et al., 1985) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Unscheduled DNA synthesis Rat hepatocytes Up to 10000 µg/ml Negative (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
(+)-alpha-pinene (pin-2(3)-ene) 
(isomer of [01.004]) 
Ames test 
(plate incorporation method) 
S. typhimurium TA97a ; TA98; TA100; 
TA1535 
Up to 1000 µg/plate 
(18 concentrations) 
Negative (Gomes-Carneiro et al., 
2005a) 
Valid studies. 
(-)-alpha-pinene (pin-2(3)-ene) 
(isomer of [01.004]) 
Ames test 
(plate incorporation method) 
S. typhimurium TA97a ; TA98; TA100; 
TA1535 
Up to 4000 µg/plate 
(19 concentrations) 
Negative (Gomes-Carneiro et al., 
2005a) 
Valid studies. 
(Pin-2(10)-ene [01.003]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
Up to 5000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate  
(4.1, 41, 410, 4100 
µg/plate) 
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
5 µl/plate  
(4290 µg/plate) 
Negative1 (DeGraff, 1983a) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Sister chromatid exchange Chinese hamster ovary cells Up to 1000 µM (136.2 
µg/ml) 
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
(Camphene [01.009]) Ames test S. typhimurium  
TA98; TA100 
0.05 - 100 µl/plate  
(42.1 - 84,500 µg/ plate) 
Negative2 (Rockwell and Raw, 
1979) 
Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA98; TA100; 
UTH8414; UTH8413 
0, 10 to 1000 µg/plate (5 
concentrations) 
Negative1 (Conner et al., 1985) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Sister chromatid exchange test Chinese hamster ovary cells 10 - 1000 µM  
(1.4 - 136.2 µg/ml) 
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
(beta–Caryophyllene [01.007]) Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
150,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test S. typhimurium TA98; TA100; TA1535; 
TA1537; TA1538 
150 µl/plate Negative1 (Lorillard, 1984) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test  
(plate incorporation method) 
S. typhimurium TA98; TA100; TA102; 
TA1535; TA1537 
10,000 µg/plate Negative1 (Longfellow, 1998) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Sister chromatid exchange test Chinese hamster ovary cells 1000 µM (204.4 µg/ml) Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Naphthalene [01.053] Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(3.9, 39, 385, 3850 
g/plate) 
Negative1 (Florin et al., 1980) Published non-GLP study. Part of a larger 
mutagenicity screening study evaluating 239 
compounds. Due to the limited report of 
experimental details and results the validity of 
the study cannot be evaluated. Cytotoxicity 
observed at doses >3 µM/plate.  
Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
0, 3, 10, 30, 100, 300 
µg/plate 
Negative1 (Godek et al., 1985) Unpublished GLP study carried out according to 
OECD guideline 471. 
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Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
0, 3, 10, 30, 100, 300 
µg/plate 
Negative1 (Stankowski, 1987) Unpublished GLP study carried out according to 
OECD guideline 471. Repeat confirmation of 
Ames test by Godek et al, 1985. 
Ames test  
(preincubation method) 
S. typhimurium  
TM677 
0, 1, 2 mM (0, 128, 256 
µg/ml) 
Negative2 (Kaden et al., 1979) Published non-GLP study of limited validity 
(only one strain, concentrations used were 
cytotoxic, insufficient report of experimental 
details and results). 
Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
Up to 100 µg/plate Negative2 (McCann et al., 1975) Published summary report of a large study 
evaluating the mutagenic potential of 300 
chemicals. Due to the limited report of 
experimental details and results the validity of 
the study cannot be evaluated. 
Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0, (0.3), 1, 3.3, 10, 33, 
100 µg/plate 
Negative1 (Mortelmans et al., 
1986)  
(NTP, 1992g) 
Published summary report including detailed 
results from studies on 270 compounds tested in 
various laboratories within the NTP to a large 
extent in accordance with OECD guideline 471. 
Study design and detailed results on naphthalene 
also included in NTP, 1992g. In the absence of 
metabolic activation the concentration of 100 
microgram/plate was completely toxic and not 
tested any more in the second trial when 0.3 
microgram/plate was used as additional 
concentration. In the presence of metabolic 
activation the highest concentration was slightly 
toxic. 
Ames test  
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
0, 5, 10, 25, 50, 100, 300 
µg/plate (-S9) 
0, 10, 25, 50, 100, 300, 
900 µg/plate (+ S9) 
Negative1 (Lawlor, 1994) Unpublished GLP study carried out in 
accordance with OECD guideline 471. 
Cytotoxicity was observed in a preliminary 
study at 66.7 microgram/plate and above in the 
absence of S9 mix and at 333 microgram/plate 
and above in the presence of S9 mix. 
Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; UTH8414; UTH8413 
0, 100, 500, 1000, 2000 
µg/plate 
Negative1 (Conner et al., 1985) Published non-GLP study with insufficient 
report of some details of method and results. 
Thus, the validity of the study cannot be 
evaluated. Cytotoxicity not reported. 
Ames test  
(plate incorporation method) 
S. typhimurium  
TA97; TA98; TA100 
0, 5, 10, 50, 250 µg/plate Negative1 (Sakai et al., 1985) Published non-GLP study of acceptable quality. 
Cytotoxicity was observed at the highest 
concentration with complete toxicity in TA97 
(+/-S9) and in TA100 (-S9) and a reduced 
number of mutants in TA100 (+S9) and in TA98 
(+/-S9). 
Ames test  
(plate incorporation) 
S. typhimurium 
TA98; TA100; TA1535; TA1537; 
TA1538 
0, 3.3 to 10,000 µg/plate  Negative1 (Longfellow, 1991) Only summary from CCRIS database available 
from. Validity of the study cannot be evaluated. 
Ames test  
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537  
E. coli WP2uvrA 
1 to 100 µg/plate 
 
10 to 10,000 μg/plate 
Negative1 (Japan Chemical 
Industry) 
Only summary from CCRIS database available 
from. Validity of the study cannot be evaluated. 
Rec assay E. coli  
WP2 and WP100 uvrA- recA- 
0 to 2000 µg/plate 
(≥ 4 concentrations) 
Negative2 (Mamber et al., 1984) Published non-GLP study with adequate study 
design, however, deficient in the report of some 
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Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
details on method and results (no single doses, 
no detailed results, no data on cytotoxicity 
reported). 
Inductest  
(prophage induction test) 
E. coli  
GY5027 envA- uvrB- (λ ); GY4015 ampR 
0 to 2000 µg/plate 
(≥ 4 concentrations) 
Negative2 (Mamber et al., 1984) Published non-GLP study with adequate study 
design, however, deficient in the report of some 
details on method and results (no single doses, 
no detailed results, no data on cytotoxicity 
reported). 
Unscheduled DNA synthesis test Primary rat hepatocytes 0, 0.16, 0.5, 1.6, 5, 16, 50, 
166, 500, 1666, 5000 
µg/ml 
Negative (Barfknecht et al., 
1985) 
Unpublished GLP-study according to OECD 
guideline 482. Excessive cytotoxicity observed 
at 50 to 5000 microgram/ml. 
Sister chromatid exchange test Chinese hamster ovary cells 0, 2.7, 9, 27, 45, 90 µg/ml 
(-S9) 
0, 9. 15, 27, 90 µg/ml 
(+S9) 
Positive1 (NTP, 1992g) Valid study in accordance with OECD guideline 
479. No data on cytotoxicity reported. 
According to the study protocol the highest dose 
chosen was limited by cytotoxicity. 
Significant dose-related increase in frequency of 
SCE at concentrations from 27 - 90 µg/ml 
(without metabolic activation) and 15 - 27 µg/ml 
(with metabolic activation). Maximum values 
for the percent increase in SCEs/chromosome in 
cultures exposed to naphthalene relative to those 
exposed to solvent of 40 and 50 % were reached 
at the highest dose tested in the presence and 
absence of S9, respectively, whereas values of 
360 – 640 % were reached with the positive 
control mitomycin C. Result is considered 
positive by NTP since the increase over solvent 
control observed is ≥ 20 % (NTP, 1992g; 
Galloway et al., 1987). 
Results would be considered negative by UK 
HSE as the increase in SCEs per cell does not 
reach the required minimum of at least 100 
%)(EU RAR, 2003). 
Sister chromatid exchange test Human peripheral mononuclear 
leukocytes 
100 µM 
(13 µg/ml) 
Negative1 (Tingle et al., 1993; 
Wilson et al., 1995) 
Published non-GLP study of limited validity 
(only one concentration tested). Naphthalene 
was not cytotoxic to the dividing lymphocytes 
with and without metabolic activation at the 
concentration tested. 
Mammalian cell gene mutation test 
(Mouse lymphoma assay) 
Mouse lymphocytes L5178Y tk+/tk- 0, 22 to 87 µg/ml (-S9) 
0, 8 to 30 μg/ml (+S9) 
Negative3
Positive2 
(Longfellow, 1991) Only summary from CCRIS database available. 
Validity of the study cannot be evaluated. 
Chromosomal aberration assay Chinese hamster ovary cells 15 to 75 µg/ml (-S9) 
30 to 67.5 µg/ml (+S9) 
Negative3 
Positive2 
(NTP, 1992g) Study carried out in accordance with OECD 
guideline 473, except that data on cytotoxicity 
are not reported. According to the study protocol 
the highest dose chosen was limited by 
cytotoxicity. Study is considered valid. The 
structural aberrations did not include gaps. In 
the presence of S9 the percent of cells with 
structural aberrations was significantly (p ≤ 
0.05) elevated at all concentrations tested 
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Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
compared to controls and the increase was 
significantly dose-related (p ≤ 0.001). A 
maximum of 32 % of cells with aberrations was 
reached at the highest concentration vs. 0 - 1.5 
% in negative and up to 52 % in positive 
controls. Result is considered positive by NTP 
since a statistically significant difference is 
observed for two or more doses (Galloway et al., 
1987a). 
(1-Methylnaphthalene [01.014]) Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.3, 43, 427, 4266 
μ g/plate) 
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Ames test  
(preincubation method) 
S. typhimurium  
TM677 
0, 0.7, 3.5, 7 mM (0, 498, 
995 µg/ml) 
Negative2 (Kaden et al., 1979) Abstracted by JECFA at their 63rd meeting 
(JECFA, 2006a). 
Chromosomal aberration assay Human lymphocytes 0, 1, 2 mM (0, 142, 284 
µg/ml) (-S9) 
 
0, 0.25, 0.5, 1, 2 mM (0, 
36, 71, 142, 284 μg/ml) 
(+S9) 
Negative1 (Kulka et al., 1988) Published non-GLP study largely in accordance 
with OECD guideline 473. Even if cytotoxicity 
data are not reported, the study is considered 
acceptable. The highest dose did not impair cell 
proliferation. No evidence for differences in the 
incidences of structural chromosomal 
aberrations (chromatid breaks, no exchanges 
seen) and gaps between treated and untreated 
cells (p ≤ 0.05). 0.5 to 2.0 % of treated cells 
showed aberrations (gaps excluded) vs. 1 % of 
control cells. 
Sister chromatid exchange test Human lymphocytes 0, 1, 2 mM (0, 142, 284 
µg/ml) (-S9) 
 
0, 0.25, 0.5, 1, 2 mM (0, 
36, 71, 142, 284 μg/ml) 
(+S9) 
Negative3 
 
Positive2 
(limited 
evidence) 
(Kulka et al., 1988) Published non-GLP study largely in accordance 
with OECD guideline 479. Cytotoxicity data not 
reported. The highest dose did not impair cell 
proliferation. In the presence of S9 the SCE 
frequency was significantly increased at each 
dose. An increase of 43 % was reported at the 
highest dose compared to the control. The effect 
was dose-related, but with a less marked 
increase at higher doses (saturation). 
According to OECD and NTP criteria the result 
in the presence of S9 is considered positive 
(significant increase, dose-relation, increase ≥ 
20 % over solvent control). The authors of the 
study refer to the UK HSE guidelines on 
mutagenicity testing that require at least a 
doubling in SCE frequency for a positive 
response. 
2-Methylnaphthalene [01.051] Ames test 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
0.03, 0.3, 3, 30 µM/plate 
(4.3, 43, 427, 4266 
µg/plate) 
Negative1 (Florin et al., 1980) Published non-GLP study. Part of a larger 
mutagenicity screening study evaluating 239 
compounds. Due to the limited report of 
experimental details and results the validity of 
the study cannot be evaluated. Bacterial toxicity 
observed at doses >3 µM/plate. 
Chromosomal aberration assay Human lymphocytes 0, 2.0, 4.0 mM (0, 284, Negative3 (Kulka et al., 1988) Published non-GLP study largely in accordance 
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Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
569 microgram/ml) (-S9) 
 
0, 0.25, 0.5, 1.0, 2.0, 4.0 
mM (0, 35.6, 71.1, 142, 
284 and 569 
microgram/ml) (+S9) 
 
 
Positive2 
(limited 
evidence) 
with OECD guideline 473. Even if cytotoxicity 
data are not reported, the study is considered 
acceptable. The highest dose did not impair cell 
proliferation. In the presence of S9 a statistically 
significant but weak increase (6.5fold above 
control) of structural aberrations (chromatid 
breaks, no exchanges seen) was observed at the 
highest tolerated dose (4 mM)The percent of 
cells with structural aberrations (excluding gaps) 
showed a dose-related increase (up to 5 % vs. 
1.0 % in negative and 40 % in positive controls), 
however, the increase was not reported as 
statistically significant. A dose-dependent weak 
increase of gaps was also noted over the 
concentration range tested in the presence of S9. 
According to OECD and NTP criteria there is a 
weak evidence for a positive response since a 
statistically significant difference for structural 
aberrations per cell is observed for one dose 
(NTP, 1992g; (Galloway et al., 1987a) and the 
effect was dose-related (OECD guideline 473). 
Sister chromatid exchange test Human lymphocytes 0, 2.0, 4.0 mM (0, 284, 
569 microgram/ml) (-S9) 
 
0, 0.25, 0.5, 1.0, 2.0, 4.0 
mM (0, 36, 71, 142, 284 
and 569 microgram/ml) 
(+S9) 
Negative3 
 
 
Positive2 
(limited 
evidence) 
(Kulka et al., 1988) Published non-GLP study largely in accordance 
with OECD guideline 479. Even if cytotoxicity 
data are not reported, the study is considered 
acceptable. The highest dose did not impair cell 
proliferation. In the presence of S9 the SCE 
frequency was significantly increased at each 
dose. An increase of 80 % was reported at the 
highest dose compared to the control. The effect 
was dose-related. 
According to OECD and NTP criteria the result 
in the presence of S9 is considered positive 
(significant increase, dose-relation, increase ≥ 
20 % over solvent control). The authors of the 
study refer to the UK HSE guidelines on 
mutagenicity testing that require at least a 
doubling in SCE frequency for a positive 
response. 
NR: Not Reported. 
1 With and without S9 metabolic activation.  
2 With metabolic activation.  
3 Without metabolic activation. 
4 Plate incorporation. 
5 Pre-incubation. 
6 An Ames test with cedrene washed (unspecified cedrene) was also submitted, but an adequate identification of the substance studied was not possible. Therefore the study is not further discussed. 
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In vivo mutagenicity/genotoxicity data are available for one candidate substance of the present flavouring group evaluation, for two supporting substances 
evaluated by JECFA at the 63rd meeting and for one structurally related non-Register substance (2-Methylbuta-1,3-diene). Substances listed in brackets are 
JECFA-evaluated substances. 
Table 2.4: GENOTOXICITY (in vivo) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
(2-Methylbuta-1,3-diene) In vivo Chromosomal 
aberration assay 
Mouse (B6C3F1) 
bone marrow 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 1) 
 
0, 70, 220, 700 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 2) 
Negativ
e 
(Tice et al., 1987; Tice, 
1988; Shelby, 1990) 
Unpublished study report and published summary report 
of a valid multiple endpoint cytogenicity study sponsered 
by NTP, roughly in accordance with OECD guideline 
475 (special dosage regimen used). 
 In vivo Sister chromatid 
exchange test 
Mouse (B6C3F1) 
bone marrow 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 1) 
 
0, 70, 220, 700 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days (Trial 2) 
Positive 
 
(Tice et al., 1987; Tice, 
1988; Shelby, 1990) 
Unpublished study report and published summary report 
of valid cytogenicity study sponsered by NTP. The study 
is considered valid. 
Significant (0.01 < p < 0.05) increase in the frequency of 
SCE in the bone marrow cells at all concentrations. In 
addition, a significant delay in bone marrow cellular 
proliferation kinetics (lengthening of the generation 
time) was detected. The mitotic index was not 
significantly altered. 
 In vivo Micronucleus 
test 
Mouse (B6C3F1) 
peripheral blood cells 
(male mice) 
Inhalation 0, 438, 1750, 7000 ppm for 6 
hours/day for 12 exposures over a 
period of 16 days 
Positive 
 
(Tice et al., 1987; Tice, 
1988) 
Unpublished study report and published summary report 
of valid cytogenicity study sponsored by NTP, roughly 
in accordance with OECD guideline 474 (special dosage 
regimen used). The study is considered valid.  
Significant (p<0.001) increase in the frequency of 
micronucleated polychromatic and normochromatic 
erythrocytes, and percentage of PCE. A significant 
(p<0.001) and dose-dependent decrease in the 
percentage of circulating polychromatic erythrocytes 
(suppression of erythropoiesis) was noted. 
 In vivo Micronucleus 
test 
Rat lung fibroblasts 
(male and female 
rats) 
Inhalation 0, 220, 700, 7000 ppm for 13-
weeks 
Negativ
e 
(Khan and Heddle, 
1991) 
Study carried out within NTP. Only tabulated results 
available from NTP TR 486 (NTP, 1999). Unusual study 
protocol. Validity of the study cannot be evaluated.  
(Myrcene [01.008]) In vivo Chromosomal 
aberration assay 
Rat (Wistar) bone 
marrow 
Gavage 0, 100, 500, 1000 mg/kg bw 
(single exposure) 
Negativ
e 
(Zamith et al., 1993) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
 In vivo Micronucleus 
test 
Mouse (B6C3F1)  
peripheral blood cells 
Gavage 0, 250, 500, 1000, 2000 mg/kg bw 
(single exposure) 
Negativ
e 
(NTP, 2003c) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
 Micronucleus assay  Mouse peripheral 
blood cells  
Gavage 250, 500, 1000 mg/kg bw/ day Negativ
e 
(NTP, 2010b)  
(d-Limonene [01.045]) In vivo Comet assay Mouse (ddY) / Rat 
(Wistar). 
Oral 0, 2000 mg/kg  Negativ
e 
(Sekihashi et al., 2002)  
 In vivo Mammalian spot 
test 
Mouse embryos from 
C57BL/6JHan x T 
stocks 
Intraperitoneal 
injection 
215 mg/kg bw  Negativ
e 
(Fahrig, 1984) Abstracted by JECFA at their 63rd meeting (JECFA, 
2006a). 
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Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
 In vivo Comet assay Rats (Sprague-
Dawley) (males) 
(Kidneys) 
Gavage 0, 1000, 2000 mg/kg bw (single 
exposure) 
Negativ
e 
(Nesslany et al., 2007)  
 In vivo transgenic 
mutagenisity assay 
Rats (Big blue) 
(males) (liver, 
kidney, bladder) 
Diet 0, 525 mg/kg bw/day (10 days) Negativ
e 
(Turner et al., 2001) The author do not specify whether the tested compound 
is d- or l-limonene, and the purity of the compound is not 
stated. However, the stability of the limonene in the diet 
was measured. 
Naphthalene [01.053] In vivo Unscheduled 
DNA synthesis 
Rat hepatocytes Gavage 0, 600, 1000, 1600 mg/kg bw Negativ
e 
(Research Toxicology 
Center, 1999) 
Summarised report of unpublished study carried out in 
accordance with OECD guideline 486. Although some 
minor details of the results are not reported (viability of 
cells, individual slide values for nuclear grains and 
cytoplasmic grains) the study is considered valid. 
 In vivo Micronucleus 
test 
Mouse (Swiss ICR) 
bone marrow 
Gavage 50, 250, 500 mg/kg bw (single 
exposure) 
Negativ
e 
(Harper et al., 1984) Published non-GLP study not fully in accordance with 
OECD guideline 474 (only males tested, sampling time 
not indicated, effect on PCE/NCE ratio not reported). 
Due to the limited report of experimental details and 
results the validity of the study cannot be evaluated. 
At the dose of 500 mg/kg bw two of ten animals died. 
The dose of 1500 mg/kg bw was toxic (lethal) to all 
animals. Induction of micronuclei in benzene-treated 
mice was significantly enhanced by co-treatment with 
naphthalene at 50 and 250 mg/kg bw. 
 In vivo Micronucleus 
test 
Mouse (CD-1) bone 
marrow 
Intraperitoneal 
injection 
250 mg/kg bw (single exposure) Negativ
e 
(Sorg et al., 1985) Unpublished valid GLP-study carried in accordance with 
OECD guideline 474. Naphthalene was negative in the 
micronucleus test at the dose of 250 mg/kg bw at all of 
the time intervals tested. A harvest-time dependent 
depression in the PCE/NCE ratio was observed in 
animals treated with the test substance, which was 
statistically significant (p ≤ 0.05) at sacrifice time of 72 
hours. 
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TABLE 3: SUMMARY OF SAFETY EVALUATIONS 
Table 3.1: Summary of Safety Evaluation of 24 Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005c) 
Table 3.1: Summary of Safety Evaluation of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005c)) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] (JECFA) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on 
the material of 
commerce 
01.002 
1325 
1-Isopropyl-4-methylbenzene 926 
472 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
estimated levels of 
intake as flavouring 
substances based on 
the MSDI approach. 
01.003 
1330 
Pin-2(10)-ene 1300 
759 
Class I 
A3: Intake below threshold 
4) Additional data required.  
01.005 
1331 
Terpinolene 660 
70 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
estimated levels of 
intake as flavouring 
substances based on 
the MSDI approach. 
01.006 
1328 
alpha-Phellandrene 79 
410 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
estimated levels of 
intake as flavouring 
substances based on 
the MSDI approach. 
01.007 
1324 
beta-Caryophyllene 330 
508 
Class I 
A3: Intake below threshold 
4) Additional data required. Composition of 
mixture to be 
specified. 
01.009 
1323 
Camphene 13 
28 
Class I 
A3: Intake below threshold 
4) Additional data required. Composition of 
mixture to be 
specified. 
01.010 
1333 
1-Isopropenyl-4-methylbenzene 18 
0.3 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
estimated levels of 
intake as flavouring 
substances based on 
the MSDI approach. 
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Table 3.1: Summary of Safety Evaluation of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005c)) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] (JECFA) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on 
the material of 
commerce 
01.016 
1336 
1,4(8),12-Bisabolatriene 13 
10 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
estimated levels of 
intake as flavouring 
substances based on 
the MSDI approach. 
01.017 
1337 
Valencene 53 
26 
Class I 
A3: Intake below threshold 
4) Additional data required. Composition of 
mixture to be 
specified. 
01.018 
1338 
beta-Ocimene 
(E, E)- isomer shown  
55 
11 
Class I 
A3: Intake below threshold 
4) Additional data required. Stereoisomeric 
composition to be 
specified. 
Composition of 
mixture to be 
specified. 
01.019 
1339 
alpha-Terpinene 28 
93 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Composition of 
mixture to be 
specified. 
01.020 
1340 
gamma-Terpinene 1200 
321 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Composition of 
mixture to be 
specified. 
01.024 
1345 
beta-Bourbonene H
H H
ND 
0.2 
Class I 
A3: Intake below threshold 
4) Additional data required. 
MSDI based on USA 
production figure. 
Composition of 
mixture to be specified 
MSDI based on USA 
production figure. 
01.026 
1347 
1(5),7(11)-Guaiadiene 
S
S
0.012 
3 
Class I 
A3: Intake below threshold 
4) Additional data required. Composition of 
mixture to be 
specified. 
01.029 
1342 
delta-3-Carene 290 
40 
Class I 
A3: Intake below threshold 
4) Additional data required. Composition of 
mixture to be 
specified. 
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Table 3.1: Summary of Safety Evaluation of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005c)) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] (JECFA) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on 
the material of 
commerce 
01.040 
1343 
alpha-Farnesene 
 
0.61 
40 
Class I 
A3: Intake below threshold 
4) Additional data required. Composition of 
mixture to be 
specified. 
 
 
01.061 
1341 
Undeca-1,3,5-triene  0.24 
0.2 
Class I 
A3: Intake below threshold 
4) Additional data required. Stereoisomeric 
composition to be 
specified. 
Composition of 
mixture to be 
specified. 
01.077 
1344 
1-Methyl-1,3-cyclohexadiene 
 
0.012 
313 
Class I 
A3: Intake below threshold 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
No safety concern at 
estimated levels of 
intake as flavouring 
substances based on 
the MSDI approach. 
01.008 
1327 
Myrcene 
 
290 
153 
Class I 
 A3: Intake above 
threshold, A4: Not 
endogenous,  
A5: Adequate NOAEL 
exists 
4) Additional data required. 
The JECFA used a MSDI 
of 7100 μg/capita/day 
(New data received). 
 
Composition of 
mixture to be 
specified. 
01.004 
1329 
Pin-2(3)-ene 
 
1800 
2444 
Class I 
A3: Intake above threshold, 
A4: Not endogenous,  
A5: Adequate NOAEL 
exists 
4) Additional data required. Composition of 
mixture to be 
specified. 
01.045 
1326 
d-Limonene 34000 
12726 
Class I 
A3: Intake above threshold, 
A4: Not endogenous,  
A5: Adequate NOAEL 
exists 
4) No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Composition of 
mixture to be 
specified. 
01.011 
1334 
4-Methyl-1,1'-biphenyl 
 
0.0085 
0.08 
Class III 
A3: Intake below threshold 
4) The Panel concluded that 
the substance cannot be 
evaluated through the 
Procedure due to concern 
with respect to 
genotoxicity/carcinogenicit
y. 
 
01.013 
1332 
Biphenyl 
 
0.00085 
0.7 
Class III 
A3: Intake below threshold 
4) The Panel concluded that 
the substance cannot be 
evaluated through the 
Procedure due to concern 
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Table 3.1: Summary of Safety Evaluation of Aliphatic, Alicyclic and Aromatic Hydrocarbons (JECFA, 2005c)) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure 
path 3) 
Outcome on the 
named compound  
[4) or 5)] (JECFA) 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
 
EFSA conclusion on 
the material of 
commerce 
with respect to 
genotoxicity/carcinogenicit
y. 
01.014 
1335 
1-Methylnaphthalene 0.73 
0.06 
Class III 
A3: Intake below threshold 
4) Additional data required.  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
 
ND: not determined. 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (EFSA / FGE.25Rev2)  
Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
01.001 
 
Limonene 
 
4000 
 
Class I 
A3: Intake above threshold; 
A5: Adequate NOAEL exist 
4) 6)  
01.027 
 
Bisabola-1,8,12-triene 0.024 
 
Class I 
A3: Intake below threshold 
4) 7)  
01.028 
 
beta-Bisabolene 2.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.033 
 
2,2-Dimethylhexane 1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.034 
 
2,4-Dimethylhexane 1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.038 
 
Dodecane  0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
01.039 
 
delta-Elemene 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.046 
 
l-Limonene 
 
2100 
 
Class I 
A3: Intake above threshold; 
A5: Adequate NOAEL exist 
4) 6)  
01.054 
 
Pentadecane 0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.057 
 
Tetradecane  0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
01.022 
 
alpha-Cedrene H
H
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.023 
 
1(5),11-Guaiadiene 1.2 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.030 
 
beta-Cubebene 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
01.032 
 
2,3-Dihydrofarnesene 0.12 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.035 
 
2,6-Dimethylocta-2,4,6-triene 
 
9.1 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.037 
 
Dodec-1-ene 
 
0.024 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.042 
 
Germacra-1(10),4(14),5-triene 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.043 
 
3,7,10-Humulatriene 1.2 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.044 
 
Isolongifolene 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
01.047 
 
Longifolene 
H
H
H
28 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.050 
 
3-Methylhexane 0.061 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.052 
 
alpha-Muurolene 0.24 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.055 
 
beta-Phellandrene 
 
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.056 
 
alpha-Santalene 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.059 
 
4(10)-Thujene 
 
14 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.060 
 
1,1,7-
Trimethyltricyclo[2.2.1.0.(2.6)]h
eptane 
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
01.064 
 
cis-3,7-Dimethyl-1,3,6-octatriene 
 
14 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.066 
 
2-Cedrene H
H
0.97 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.067 
 
8(14)-Cedrene HH 0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.070 
 
1-Octene  0.0085 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.078 
 
2,4-Nonadiene 
 
6.1 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.031 
 
1,2-Dihydro-1,1,6-
trimethylnaphthalene 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.058 
 
1,2,3,4-Tetrahydro-1,1,6-
trimethylnaphthalene 
0.12 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.021 
 
delta-Cadinene 0.15 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
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Table 3.2: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
01.036 
 
Diphenylmethane 1.2 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.051 
 
2-Methylnaphthalene 0.0012 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
01.053 
 
Naphthalene 0.013 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation.. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach) 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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ABBREVIATIONS 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EPA  United States Environmental Protection Agency  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practise 
ID  Identity 
Ip  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
PCE  Polychromatic erythrocyte 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
WHO  World Health Organisation 
